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ABSTRACT  
 
        Novel modified Toll-like receptor 9 (TLR9) agonists, termed immune 
modulatory oligonucleotides (IMOs), exhibit antitumor activity and are 
currently investigated in cancer patients. Intriguingly, their mechanisms of 
action on tumor growth and angiogenesis are still incompletely understood. 
Using an IMO recognizing human and murine TLR9, we recently 
discovered that IMO acts by impairing Epidermal Growth Factor Receptor 
(EGFR) signalling, cooperates with anti-EGFR drugs and boosts the 
antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-EGFR 
antibodies. IMO in fact cooperates with anti-EGFR antibody cetuximab in 
GEO human colon cancer xenografts, through the potentiation of 
cetuximab ADCC and the inhibition of EGFR signalling. IMO is instead 
ineffective in VEGF overexpressing cetuximab-resistant GEO-CR tumors.  
        Therefore, we used IMO and the anti-VEGF antibody bevacizumab as 
tools to study IMO’s role on EGFR and angiogenesis and to explore its 
therapeutic potential in GEO, LS174T and GEO-CR cancer xenografts. We 
found that bevacizumab has no ADCC and IMO is unable to enhance it. 
Nevertheless, IMO plus bevacizumab combination cooperatively inhibits 
the growth of GEO and LS174T preceded by inhibition of signalling 
proteins expression, microvessels formation and human, but not murine, 
VEGF secretion. Interestingly also the growth of GEO-CR tumors is 
cooperatively inhibited by this drug combination. Moreover, IMO shows a 
direct antiangiogenic activity, inhibiting survival, adhesion, migration and 
capillary formation of VEGF-stimulated endothelial cells. The antitumor 
activity was irrespective of the TLR9 expression on tumor cells. Therefore, 
considering that IMO creates the opportunity to take advantage of multiple 
chance for cooperativity, involving EGFR- and ADCC-dependent and -
independent mechanisms and neoangiogenesis,  we have evaluated IMO 
ability to revert mechanisms of resistance in different tumor models from 
colon cancer. Since intrinsic and acquired resistance to anti-ErbB2 antibody 
trastuzumab is becoming an increasingly relevant issue in breast cancer, we 
investigated whether the antitumor, antiangiogenic and immunostimulatory 
activity of IMO could enhance trastuzumab effect in trastuzumab-resistant 
breast cancers. We found that IMO potentiates trastuzumab-mediated 
ADCC on KPL-4 and JIMT-1 cells, naturally resistant to trastuzumab in 
vitro. IMO inhibits the growth of KPL-4 and JIMT-1 xenografts, and 
potentiates the inhibitory effect of trastuzumab, with an almost complete 
suppression of tumor growth and expression of several ErbB-related signal 
transducers by the combined treatment. The combination produces also a 
cooperative direct antiangiogenic effect. Surprisingly, TLR9 is expressed in 
KPL-4 cells and seems to functionally interact with EGFR. 
        These studies demonstrate that TLR9 agonists interfere with tumor 
and its microenvironment by multiple mechanisms providing a strong 
rationale to combine IMO with several targeted agents in cancer patients. 
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1. BACKGROUND 
 
 
1.1. Targeted antitumor therapy and mechanisms of resistance 
 
The “targeted therapy” has been defined as a new strategy based on 
antitumor agents that are able to interfere with a specific molecular target, 
typically a protein, believed to have a critical role in tumor growth or 
progression. Most of  these targets are represented by kinases controlling cell 
homeostasis. Tyrosine kinase receptors (TKRs) are able to mediate the effect of 
growth factors and sustain signal transduction pathways. One of the most 
investigated TKRs family is the erbB/HER-family, which includes four 
members defined as ErbB-1/EGFR/HER1, ErbB-2/HER2/neu, ErbB-3/HER3 
and ErbB-4/HER4 (Citri and Yarden 2006). The EGFR gene encodes a 170 
kDa trans-membrane glycoprotein containing 1186 amino acids, which consists 
of an extracellular domain that recognizes and binds to specific ligands, a 
hydrophobic trans-membrane domain, involved in interactions between 
receptors within the cell membrane, and an intracellular domain that serves as 
the site of protein kinase activity. Ligand-binding induces either homo- or 
heterodimerization between EGFR and other members of the HER-family and 
EGFR function and activity are strictly regulated by these interactions 
(Lemmon and Schlessinger 1994). While ErbB-2 exists in an activated and 
ligand-independent three-dimensional structure,  ErbB3 seems to be a non-
autonomous receptor, since its kinase activity is defective, but it is able to form 
heterodimeric complexes with other ErbB receptors generating potent cellular 
signals. The ligands of the ErbB receptors belong to the EGF-family of growth 
factors, usually divided into three groups: EGF, transforming growth factor 
alpha (TGF-α) and amphiregulin (AR), bind to the EGFR; betacellulin (BTC), 
heparin-binding growth factors (HB-EGF), epiregulin (EPR) and heregulins 
(HRG) have dual binding specificity for EGFR and ErbB4; the neuregulins 
(NRGs) are able to bind ErbB3 and/or ErbB4 (Yarden 2001). EGF-related 
growth factors have different affinity for the members of HER-family and are 
characterized by the presence of an EGF-like domain composed of three 
disulfide-bonded intramolecular groups conferring binding specificity, and 
additional structural motifs such as immunoglobulin-like domains, heparin-
binding sites and glycosylation sites (Sebastian et al. 2006). Ligand-binding 
induces a conformational change of the receptor leading off the dimerization 
process (Ferguson 2004). The autophosphorylated receptor initiates the 
recruitment to the plasma-membrane and activates trough phosphorylation 
other cytoplasmic substrates, which, in turn, mediate the activation of different 
signal transduction pathways depending upon the type of ligand, levels of 
receptor expression and partners of dimerization. The most studied downstream 
pathways include the PI3K/Akt, Ras/ERK and PLCγ/PKC signalling cascades 
(Scaltriti and Baselga 2006).  
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Aberrant activity of ErbB signalling is associated with cancer 
development and growth and is initiated by several events, such as altered 
ligand production, receptor mutations, deletions, or persistent activation. High 
levels of EGFR or ErbB2 expression are a common feature of the malignant 
phenotype in many solid human tumors, and may result from a variety of 
mechanisms including increased gene transcription or gene amplification 
(Milanezi et al. 2008). Several studies have demonstrated that EGFR or ErbB2 
expression correlates with reduced disease-free and overall survival, poor 
prognosis, increased risk of disease recurrence, advanced tumor stage, and 
increased risk of metastasis (Scaltriti and Baselga 2006). High expression of 
ErbB ligands in conjunction with increased expression of ErbB receptors may 
facilitate the development of an autocrine/paracrine growth pathway, 
contributing to carcinogenesis. Gene amplification leading to EGFR or ErbB2 
overexpression is a frequent feature of human cancers (Milanezi et al. 2008), 
often accompanied by other structural rearrangements that cause in-frame 
deletions in the extra-cellular domain of the receptor. The most frequent 
deleted form of the human EGFR is the type-III variant (EGFRvIII), 
characterized by a deletion in the extra-cellular domain that leads to 
constitutive activation of its TK domain (Kuan et al. 2001). Besides 
perturbations in EGFR or ErbB2 expression, mutations and ligand production, 
downstream intracellular signalling pathways under receptors control are 
frequently altered in tumor cells, ensuring survival, metastatic spread and 
resistance to therapies: Ras, PTEN and STAT mutations are often present in 
human cancers (Bianco et al. 2003; Friday and Adjei 2005; Cochet et al. 2005).  
The role of ErbB-related signal transduction pathways in cancer 
development induced pharmaceutical companies to devote efforts to the 
development of inhibitors, producing remarkable results in several human 
malignancies. Among the ErbB targeting agents, there are monoclonal 
antibodies (MAbs) that bind the extra-cellular domain of the receptor and 
compete with endogenous ligands; small-molecules tyrosine kinase inhibitors 
(TKIs) that bind the intracellular portion of the receptor, generally by 
competing with ATP and inhibiting receptor autophosphorylation; 
immunotoxin conjugates that deliver toxins; antisense oligonucleotides or 
siRNA that decrease the expression of the receptor; soluble ligand trap; 
receptor decoys or polypeptides; drugs targeting transduction molecules 
downstream to the ErbB signalling (Hynes and Lane 2005).  
The most promising and well studied ErbB inhibitors are MAbs and 
TKIs. They share the same target but display different mechanisms of action 
and different specificity for the target; in fact, MAbs are exclusively specific, 
while TKIs are relatively specific. Moreover, MAbs are able to induce receptor 
internalization, down-regulation, degradation and activation of host immune 
response via antibody-dependent cell-mediated cytotoxicity (ADCC). These 
features may contribute to the observed differences in efficacy and toxicity 
profiles (Ciardiello and Tortora 2008). Among EGFR inhibitors, two anti-
EGFR monoclonal antibodies (cetuximab and panitumumab) and two small-
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molecules, reversible EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) 
have been approved in several countries for the treatment of various human 
cancer types, but more than ten EGFR-targeting agents are actually in 
advanced clinical development (Garofalo et al. 2008). Approximately 20% to 
25% of invasive breast cancers exhibit overexpression of ErbB2. As elevated 
ErbB2 levels are associated with reduced disease-free and overall survival in 
metastatic breast cancer (MBC), therapeutic strategies are being developed to 
target this oncoprotein (Nahta and Esteva 2006). Trastuzumab, a recombinant 
humanized monoclonal antibody directed against an extracellular region of 
ErbB2, was the first ErbB2-targeted therapy approved by the United States 
Food and Drug Administration (FDA) for the treatment of HER2-
overexpressing MBC. Trastuzumab with adjuvant chemotherapy (in sequence 
or in combination) significantly improved disease-free and overall survival 
rates in patients with early stage ErbB2-overexpressing breast cancer (Romond 
et al. 2005).  
A relevant issue in cancer patients is the development of primary and 
secondary resistance to anti-ErbB drugs. Primary or constitutive resistance 
refers to patients who either do not achieve stable disease or who progress 
within 6 months after an initial clinical response, whereas secondary or 
acquired resistance typically occurs after prolonged treatment. However, it is 
not possible to define the molecular basis of each type of resistance. The 
mechanisms of resistance to targeted agents are similar to cytotoxic agent 
resistance such as inactivating metabolism, poor absorption, reduced drug 
availability or defective immune system-mediated functions. However, most 
relevant causes of targeted drug resistance are specific mutations or loss of the 
target, activation of alternative TK receptors that bypass the pathway targeted 
by the specific agent, independent or constitutive activation of intracellular 
molecular effectors downstream to the target protein, and activation of tumor-
induced angiogenesis (Tortora et al. 2007).  
The rate of primary resistance to single-agent trastuzumab for ErbB2-
overexpressing MBC is 66% to 88%, therefore, elucidating the molecular 
mechanisms underlying primary or acquired trastuzumab resistance is critical 
in order to improve the survival of MBC patients whose tumors overexpress 
ErbB2 and to identify novel therapeutic targets toward the goal of increasing 
the magnitude and duration of response to trastuzumab-based treatment.  
(Nahta and Esteva 2006; Friedländer et al. 2008). A potential mechanism by 
which resistance to targeted antibodies may develop is via disruption of the 
interaction between the therapeutic agent and the target protein. Resistance to 
trastuzumab was associated with increased expression of the membrane-
associated glycoprotein MUC4 that  bind and sterically hinder ErbB2 from 
binding to trastuzumab. MUC4 interacts directly with ErbB2 through its EGF-
like domain and serves as a ligand for ErbB2, resulting in increased 
phosphorylation of the receptor on the residue Tyr1248 (Nagy et al. 2005). The 
JIMT-1 trastuzumab-resistant cell line was established from a breast cancer 
patient showing her2 gene amplification and primary resistance to trastuzumab. 
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Using this model, the authors demonstrated that the level of MUC4 protein was 
inversely correlated with the trastuzumab binding capacity, and showed that 
knockdown of MUC4 increased the sensitivity of JIMT-1 cells to trastuzumab. 
Thus, the authors proposed that elevated MUC4 expression masks the 
trastuzumab binding epitopes of ErbB2 that is also unable to interact with other 
proteins, such as EGFR or ErbB3, because of epitope masking by MUC4 
(Tanner et al. 2004). Trastuzumab resistance has been also associated with 
increased signalling from the insulin-like growth factor-I receptor (IGF-IR). 
Increased expression of IGF-IR was shown to reduce trastuzumab-mediated 
growth arrest of ErbB2-overexpressing breast cancer cells. Crosstalk occurs 
between IGF-IR and ErbB2, and showed that IGF-IR physically interacts with 
and phosphorylates ErbB2 in trastuzumab-resistant cells, but not in 
trastuzumab-sensitive parental cells (Lu et al. 2001). It has been demonstrated 
that p27kip1 is a critical mediator of trastuzumab response, and that its 
downregulation may occur subsequent to increased signalling from growth 
factor receptors such as IGF-IR, promoting resistance to trastuzumab (Nahta et 
al. 2004). Moreover, also PTEN and PI3K signalling are associated with 
trastuzumab resistance. Constitutive PI3K/Akt activity, resulting fom the loss 
of  PTEN phosphatase, was previously shown to inhibit cell-cycle arrest and 
apoptosis mediated by trastuzumab. Patients with PTEN-deficient ErbB2-
overexpressing breast tumors have a much poorer response to trastuzumab-
based therapy (Nagata et al. 2004). Finally, another mechanism of trastuzumab 
resistance is related to serum ErbB2 extracellular domain. The full-length 185 
kDa ErbB2 protein has been reported to be cleaved by matrix metalloproteases 
into a 110 kDa extracellular domain (ECD), which is released into cell culture 
media or circulating in serum in vivo (Colomer et al. 2000), and a 95 kDa 
amino-terminally truncated membrane-associated fragment with increased 
kinase activity, defined as p95HER2 (Christianson et al. 1998). Elevated serum 
levels of ErbB2 ECD correlate with poor prognosis in patients with advanced 
breast cancer. Of potential importance, trastuzumab blocked ErbB2 ECD 
proteolytic cleavage in vitro (Molina et al. 2001). ErbB2-targeted monoclonal 
antibodies bind to circulating ECD, competing away binding to membrane-
bound ErbB2. Hence, signalling from the receptor form of ErbB2 continued in 
the presence of ErbB2 antibodies, indicating that ErbB2 ECD promoted 
resistance to ErbB2-targeted antibody therapy (Zabrecky  et al. 1991). The 
p95HER2 protein may be generated by different, nonmutually exclusive, 
mechanisms, including not only the extracellular domain shedding, but also 
alternative RNA processing (Scott et al. 1993) or alternative initiation of 
translation from different methionines within the her2 sequence (Anido et al. 
2006). However, the presence of these truncated forms of ErbB2 may promote 
resistance to trastuzumab. 
One of the most relevant causes of EGFR/ErbB-2 inhibitors resistance 
is the activation of tumor-induced angiogenesis. Angiogenesis is crucial for 
local tumor growth and in the development of distant metastasis (Folkman 
1971; Kerbel and Folkman 2002). Different growth factors, such as basic 
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fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) 
and transforming growth factor-α (TGFα), have been identified as positive 
regulators of angiogenesis, and are secreted by cancer cells to stimulate normal 
endothelial cell growth through paracrine mechanisms (Ferrara et al. 2003). 
VEGF is a potent and specific mitogen for endothelial cells, activates the 
angiogenic switch in vivo and enhances vascular permeability (Ferrara et al. 
2003). VEGF mRNA expression is rapidly and reversibly induced in cells 
exposed to hypoxia, occurring in poorly vascularized tumors, via the Hypoxia-
inducible factors (HIF), a heterodimeric protein consisting of HIF-1α and HIF-
1β, which, by binding to hypoxia-response elements, controls the transcription 
of genes involved in cell proliferation/survival, invasion/metastasis and 
angiogenesis, including VEGF (Melillo 2007). In mammals, the vascular 
endothelial growth factor (VEGF) family consists of five members: VEGF-A 
(thereafter called VEGF), VEGF-B, VEGF-C, VEGF-D, and placental growth 
factor (PlGF). In addition, alternative exon splicing results in generation of 
four main VEGF isoforms denoted VEGF121, VEGF165, VEGF189, and 
VEGF206. Moreover, VEGF165 can be cleaved by plasmin and various 
metalloproteinases at the COOH terminus, generating VEGF110 or VEGF113, 
two bioactive NH2-terminal fragments (Kowanetz and Ferrara 2006). Members 
of the VEGF family show different affinities for one of the three VEGF 
tyrosine kinase receptors: VEGFR-1/Flt-1, VEGFR-2/KDR, and VEGFR-3/Flt-
4. These receptors are overexpressed on activated endothelial cells, where they 
regulate cell permeability, proliferation, and differentiation, as well as on 
hematopoietic stem cells, osteoblasts and monocytes (Ferrara et al. 2003). 
VEGF-A binds to both VEGFR-1 and VEGFR-2. VEGFR-2 appears mostly 
restricted to vascular endothelial cells while VEGFR-1 is present in both 
vascular endothelial and macrophage-like cells and may promote 
inflammation, tumor growth and metastasis (Shibuya 2006). Interestingly, 
subsets of liquid and solid tumor cells were found to express VEGFR-1 and 
VEGFR-2 (Kowanetz and Ferrara 2006). In fact, enhanced VEGF expression is 
found in human cancer cell lines and in cancer patients with different 
malignancies, including colorectal (CRC), breast, non-small-cell lung 
(NSCLC) and ovarian cancers and is directly correlated with increased 
neovascularization as measured by microvessel count (MVC) within the tumor 
(Fontanini et al. 1997). In 1971, Folkman (Folkman 1971) proposed that 
antiangiogenesis may be a novel anticancer strategy. Several pharmacologic 
approaches to inhibit the VEGF axis have been described and are considered 
another good example of targeted therapy for tumors (Kowanetz and Ferrara 
2006). The first antiangiogenic agent approved by the FDA is bevacizumab, a 
humanized version (Presta et al. 1997) of an anti-VEGF monoclonal antibody 
used in early proof-of-concept studies (Kim et al. 1993). In 2004, bevacizumab 
was approved for the treatment of previously untreated metastatic colorectal 
cancer in combination with 5-fluorouracil-based chemotherapy regimens 
(Ferrara et al. 2004). Bevacizumab is presently being tested in several phase III 
studies in combination with chemotherapy, in relapsed metastatic colorectal 
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cancer, non–small cell lung cancer, and previously untreated or relapsed 
metastatic breast cancer. Preliminary evidence of clinical benefit has been 
observed in all cases. Currently, other anti-VEGF agents are at various stages 
of clinical development. These include the following: VEGFTrap, a soluble 
receptor targeting VEGF, VEGF-B, and placental growth factor; an antisense 
oligonucleotide, VEGF-AS, targeting VEGF, VEGF-C, and VEGF-D; and 
several small-molecule tyrosine kinase inhibitors some of which have been 
recently approved by the FDA for clinical use (Kowanetz and Ferrara 2006). It 
has been previously shown that tumors acquiring resistance to anti-
EGFR/ErbB2 drugs overexpress and secrete the main proangiogenic factor 
VEGF, that acts as an escape pathway, overcoming receptor blockade (Viloria-
Petit et al. 2001). Moreover, it has been shown that VEGF overexpression 
markedly impairs the activity of dendritic cells and the antitumor immune 
response (Gabrilovich et al. 1998). These studies and the demonstration of a 
cooperative effect of cetuximab with a selective inhibitor of VEGF (Ciardiello 
et al. 2000) have provided the basis for the ongoing clinical studies combining 
inhibitors of EGFR and of VEGF/VEGFRs (Sandler and Herbst 2006). 
Interestingly, the VEGF blockade by bevacizumab recovers the activity of 
dendritic cells improving their antitumor function (Gabrilovich et al. 1999). 
 
 
1.2. TLR9 agonists as new antitumor agents 
 
Vertebrates are endowed with two complementary immune systems, the 
innate and the adaptive. The adaptive immune system is mediated by the highly 
sophisticated B and T cells, which specifically target the invader, and provide a 
memory response to prevent a repeat of the infection. The innate immune 
system, which is evolutionarily more ancient than adaptive immunity, must 
accomplish four fundamental tasks: it must rapidly detect any infectious agent, 
categorize the type of invading infectious agent, eradicate or at least 
temporarily contain the infection and finally induce the appropriate type of 
adaptive immune response to eliminate the infection and prevent its recurrence 
(Krieg 2008). The key feature of innate immune cells that enables them to 
detect and categorize infection seems to be their repertoire of Pattern-
Recognition Receptors (PRRs) that can recognize pathogen-expressed 
molecules, such as lipopolysaccharide, viral RNA or bacterial DNA, defined as 
Pathogen-Associated Molecular Patterns (PAMPs). The most well understood 
of these receptors are the Toll-like receptors (TLRs), of which a family of 10 
related molecules has been identified in humans. TLRs are transmembrane 
receptors comprising an extracellular leucine-rich repeat and a cytoplasmic 
TIR [Toll/IL-1 (interleukin-1) receptor] domain, connected through a 
transmembrane domain. Of the ten TLRs identified in humans, TLR3, 7, 8 and 
9, referred to as intracellular TLRs, are expressed on the membranes of the 
endosomes and recognize nucleosides, nucleotides and oligo- and poly-
nucleotides derived from intracellular viral and bacterial pathogens, while the 
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other six TLRs are referred to as cell-surface TLRs and recognize cell-wall 
constituents of extracellular pathogens (Agrawal and Kandimalla 2007). The 
immune role of TLR9 has been studied most extensively in plasmacytoid 
dendritic cells (pDCs) and B cells, which may be the only human immune cells 
to constitutively express TLR9 (Krieg 2008). Cellular activation is reported to 
induce TLR9 expression in additional cell types, including human neutrophils 
(Hayashi et al. 2003), monocytes and monocyte-derived cells (Saikh et al. 
2004; Siren et al. 2005) and CD4 T cells (Gelman et al. 2006), but the biologic 
role for this is less well understood. TLR9 expression has also been reported in 
some human non-immune cells, including pulmonary epithelial cells and lung 
cancers (Li et al. 2004; Platz et al. 2004; Droemann et al. 2005), keratinocytes 
(Lebre et al. 2007), intestinal epithelium (Pedersen et al. 2005; Lee et al. 2006), 
endometrial epithelium/stroma with a menstrual cycle-dependent regulation 
(Aflatoonian et al. 2007), and in gastric mucosa, where TLR9 polarization 
seems to be a process dynamically influenced by Helicobacter pylori infection 
(Schmausser et al. 2004). TLR9 recognizes and is activated by unmethylated 
cytosine-phosphate-guanine (CpG) dinucleotides, which are relatively common 
in bacterial and viral DNA but are suppressed and methylated in vertebrate 
DNA (Krieg 2006). Synthetic oligodeoxynucleotides (ODNs) that contain CpG 
motifs that are similar to those found in bacterial DNA, stimulate a similar 
TLR9 activation and are currently defined as TLR9 agonists. They are rapidly 
internalized by immune cells, perhaps involving class III phosphatidylinositol 
3-kinase (PI3K), and they interact with TLR9 that is present in endocytic 
vesicles. The interaction between TLR9 agonists and TLR9 transduces an 
intracytoplasmic activation signal. The signal initiates with the recruitment of 
myeloid differentiation primary response gene 88 (MyD88) to the Toll–
interleukin-1 receptor (TIR) domain of TLR9, followed by activation of the 
IRAK (IL-1 receptor-activated Kinase) – TRAF6 (tumor-necrosis factor 
receptor-associated factor 6) complex. This leads to the activation of both the 
mitogen-activated protein kinase (MAPK: JNK1/2 and p38) and inhibitor of 
nuclear factor-κB (NF-κB) kinase (IKK) complexes, culminating in the 
upregulation of transcription factors, including NF-κB and activating protein 1 
(AP1) (Klinman 2004). Recently, the concept that only unmethylated CpG 
motifs are thought to drive TLR9 activation and thus act as PAMPs has been 
challenged. In fact, it has been suggested that the sugar backbone determined 
DNA recognition by TLR9. Homopolymeric, base-free phospho-diester (PD) 
2’ deoxyribose acted as a basal TLR9 agonist as it bound to and activated 
TLR9. This effect was enhanced by DNA bases, even short of CpG motifs. In 
contrast, phospho-thioate (PS)-modified 2’ deoxyribose homopolymers acted 
as TLR9 antagonists. Only CpG-motifs introduced to inhibitory PS 2' 
deoxyribose converted the antagonistic activity into powerful agonistic 
function. Therefore, these new data restricted the CpG-motif dependency of 
TLR9 activation to the promising group of TLR9 agonists that are based on PS 
modified synthetic DNA, while natural PD DNA drives TLR9 activation 
sequence-independently. Thus evolutionary pressure might have exiled nucleic 
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acid recognizing TLRs such as TLR9 to endosomes in order to avoid activation 
by host (self) derived nucleic acids (Haas et al. 2008). Moreover, it has been 
demonstrated that the ectodomain of TLR9 is cleaved in the endolysosome, 
such that no full-length protein is detectable in the compartment where ligand 
is recognized. Notably, although both the full-length and cleaved forms of 
TLR9 are capable of binding ligand, only the processed form recruits MyD88 
on activation, indicating that this truncated receptor, rather than the full-length 
form, is functional. So this process prevents TLR9 from responding to self 
nucleic acids (Ewald et al. 2008). 
At a cellular level, activation of TLR9 by TLR9 agonists initiates a 
cascade of potent Th1-type  innate and adaptive immune responses. All of the 
cellular immune effects of TLR9 agonists in humans are thought to result 
directly and indirectly from activating TLR9-expressing pDC and B cells. 
TLR9 agonists activate pDCs to secrete type I interferon (IFN) and to express 
increased levels of costimulatory molecules such as CD80 (B7.1) and CD86 
(B7.2). This is believed to initiate a range of secondary effects, including 
secretion of cytokines/chemokines, such as monocyte chemoattractant protein-
1 (MCP-1) or IFN-γ-inducible 10kDa protein (IP-10), activation of natural 
killer (NK) cells, through both IFN-dependent and IFN-independent pathways, 
and expansion of T-cell populations, particularly type 1 helper T (Th1) cells 
and cytotoxic T lymphocytes (CTLs), that are capable of destroying tumor 
cells. Opposing these immune-boosting effects, pDCs activated through TLR9 
also mediate immune-suppressive effects through counterregulatory factors 
such as the generation of Tregs. In B cells, TLR9 stimulation results in the 
secretion of proinflammatory cytokines, such as IL-6, and in the release of 
immune regulatory cytokines that might limit the intensity of the inflammatory 
response, such as IL-10. TLR9 activation of B cells confers a greatly increased 
sensitivity to antigen stimulation and enhances their differentiation into 
antibody-secreting plasma cells, potentially promoting ADCC. On balance, 
these immune effects of TLR9 agonists generally promote strong Th1 CD4+ 
and CD8+ T cell responses. However, the concurrent activation of 
counterregulatory pathways such as the induction of Tregs limit TLR9-induced 
immune activation, offering a potential for enhancing the therapeutic efficacy 
of TLR9 agonists by coadministration of antagonists of one or more of these 
inhibitory pathways (Krieg 2007; Krieg 2008).  
An understanding of the immune cascade initiated by TLR9 activation 
has prompted the clinical development of several TLR9 agonists in the fields of 
infectious disease, vaccines, asthma/allergy and cancer. The innate immune 
response elicited by CpG motifs has developed to protect the host from 
infectious pathogens. Therefore, TLR9 agonists might be used as stand-alone 
agents to reduce susceptibility to infection. When combined with allergen, 
these agonists stimulate an antigen-specific T helper 1 (Th1)-cell response that 
inhibits the development of Th2-cell-mediated allergic asthma. TLR9 agonists 
also improve the function of professional antigen-presenting cells (APCs), and 
create a cytokine/chemokine milieu that is conducive to the development of an 
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adaptive immune response to co-administered vaccines (Klinman 2004). The 
rationale for investigating TLR9 agonists as anticancer agents is based on the 
hypothesis that the innate immune activation may have direct antitumor effects 
and that the enhanced tumor antigen presentation in a Th1-like cytokine and 
chemokine milieu will promote an antitumor immune response (Krieg 2008). 
In particular, in vivo dendritic cell activation through TLR9 has a key role in 
the switching on antitumor immunity. In fact, malignant tumors suppress 
immune function, and create an environment that favours the maintenance of 
T-cell tolerance, preventing the development of antitumor immunity. Dendritic 
cell activation creates a Th1-like cytokine and chemokine milieu and can up-
regulate the expression of co-stimulatory molecules on the pDCs, shifting T 
cells from tolerance, to a strong cytotoxic T-lymphocyte response against the 
tumor antigens (Krieg 2006). 
The initial impetus to develop TLR9 agonists as anticancer drugs came 
from several preclinical studies demonstrating antitumor activity in a wide 
variety of tumor models, both in monotherapy or in combination with 
traditional anticancer therapies, such as radiotherapy and chemotherapy, or 
other immunotherapies (Baines and Celis 2003; Weigel et al. 2003; Milas et al. 
2004). Mice and humans have a different TLR9 expression pattern, and 
exposure to CpG motifs stimulates a more narrow profile of 
cytokines/chemokines in humans; thus, preclinical results cannot be considered 
predictive of clinical findings (Krieg 2007). However, based on the strength of 
the extensive preclinical data, several TLR9 agonists are now being developed 
as anticancer agents. Because the phosphodiester bond of native DNA is 
rapidly degraded by endonucleases, these investigational TLR9 agonists use a 
nuclease-resistant phosphorothioate backbone that improves the half-life in the 
body from just a few minutes (for unmodified native DNA) to about 48 h 
(Krieg 2008). Coley Pharmaceutical Group (Wellesley, MA, USA) has 
developed a TLR9 agonist known as CPG 7909 that is being investigated as a 
vaccine adjuvant in several tumor types. CPG 7909 was licensed by Pfizer 
Pharmaceuticals Inc. (New York, NY, USA) for clinical investigation as a 
single agent or in combination with other therapeutic approaches, and is now 
known as PF-3512676 when it is not being used as a vaccine adjuvant. Other 
TLR9 agonists in clinical development for cancer include ISS 1018 (Dynavax 
Technologies, Berkeley, CA, USA) and CpG-28 (University of Paris, France) 
(Krieg 2008). 
A distinguishing characteristic of TLR9 agonists is their ability to 
induce strong CD4+ and CD8+ T-cell responses and rapid production of 
antigen-specific antibodies when used as a vaccine adjuvant with many types 
of antigen (Krieg 2007). These TLR9 agonists adjuvants have been heavily 
studied for the treatment of infectious diseases, and several clinical trials are 
also investigating their activity as tumor vaccines. Phase I and II trials have 
been investigating CPG 7909 as a vaccine adjuvant in patients with melanoma, 
breast cancer and renal cell carcinoma (RCC). The most advanced cancer 
vaccine program is a phase III, randomized, controlled, clinical trial of the 
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tumor antigen MAGE-A3 combined with CPG 7909 for the treatment of 
patients with early-stage (stage IB, II or IIIA), completely resected NSCLC 
whose tumors express the antigen (Krieg 2008). 
Monotherapy with TLR9 agonists has been evaluated in patients with 
hematologic malignancies, skin cancers and other solid tumors, such as 
advanced renal cell carcinoma (RCC) or recurrent glioblastoma. TLR9 agonists 
have a variety of effects on B cells that may be relevant in the treatment of 
hematologic malignancies. Activation of TLR9 on primary malignant B cells 
upregulates expression of major histocompatibility complex molecules and 
other surface receptors, thereby increasing their capacity to stimulate T cells. 
This may result in an enhanced T-cell-mediated response to tumor antigens on 
the malignant B cells. Furthermore, in patients with advanced cutaneous T-cell 
lymphoma (CTCL), NK cells and CD8+ T cells were activated following 
culturing of peripheral blood mononuclear cells with TLR9 agonists, and there 
was a marked increase in IFN-α production. This could enhance the antitumor 
immune response by activating NK cells, or may induce a direct 
antiproliferative effect (Krieg 2008). Chronic lymphocytic leukemia (CLL) 
cells, which express TLR9, are induced by TLR9 agonists to undergo 
apoptosis, in contrast with normal primary B cells in which TLR9 activation 
protects against apoptosis (Jahrsdorfer et al. 2005). Several clinical studies of 
single-agent TLR9 agonists have been completed in patients with hematologic 
malignancies, indicating that TLR9 agonists may be useful in the treatment of 
these tumors (Link et al. 2006). Because melanoma is a highly immunogenic 
tumor that has been shown to respond to immunotherapy, it is a logical 
malignancy in which to explore the activity of TLR9 agonists. Two general 
approaches have been investigated using monotherapy with PF-3512676: local 
therapy with intra- or perilesional injection and systemic therapy with s.c. 
injection. These studies demonstrated that PF-3512676 is generally well 
tolerated as a single agent in patients with melanoma or basal cell carcinoma 
(BCC) and is associated with antitumor activity (Molenkamp et al. 2007; 
Hofmann et al. 2008). Monotherapy with TLR9 agonists has also been 
evaluated in phase I trials in patients with advanced RCC or recurrent 
glioblastoma. A minor response was observed in 2 of 24 patients with recurrent 
glioblastoma receiving CpG-28 in a phase I trial  (Carpentier et al. 2006). In a 
phase I trial in 31 patients with advanced RCC receiving PF-3512676, one 
patient (3%) had a PR and nine patients (29%) had SD (Krieg 2008).  
Combination therapy with TLR9 agonists has been evaluated above all 
in patients with Non-Hodgkin’s lymphoma and NSCLC. Preclinical studies 
have indicated that the combination of a TLR9 agonist and rituximab, a MAb 
against CD20, may be more effective than rituximab alone. Two phase I 
clinical trials have investigated the combination of a TLR9 agonist with 
rituximab in patients with relapsed/refractory NHL, obtaining an overall 
response of 24% and 32% respectively. Combination therapy with TLR9 
agonists is being further evaluated for antitumor activity in a phase I/II trial in 
combination with radiation therapy and in a phase II trial in combination with 
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rituximab (Krieg 2008). Several preclinical models have also suggested that a 
TLR9 agonist can synergize with cytotoxic chemotherapy in NSCLC (Krieg 
2007). Based on both preclinical and clinical proof-of-concept studies, a 
randomized controlled phase II trial was conducted in chemotherapy-naïve 
patients with stage IIIb/IV NSCLC, suggesting that the addition of PF-3512676 
to taxane plus platinum chemotherapy for first-line treatment of NSCLC 
improves objective response and may improve survival (Manegold et al. 2008). 
Following completion of the phase II trials, two phase III studies were 
conducted exploring the combination of PF-3512676 with 
paclitaxel/carboplatin or gemcitabine/cisplatin versus chemotherapy alone as 
first-line treatment of patients with advanced NSCLC. No improvement in 
overall survival or progression-free survival was observed when PF-3512676 
was added to standard platinum-based doublet chemotherapy in either trial. 
However, there was a higher frequency of grade 3/4 neutropenia and 
thrombocytopenia and a higher frequency of ‘sepsis-like events’ and ‘septic 
deaths’ reported as serious adverse effects in the PF-3512676 plus 
chemotherapy arms. Based on the recommendation of an independent data 
monitoring safety committee, these phase III studies were terminated. The 
reason for the failure of these trials is unclear, but possible factors include the 
advanced stage of the disease, the use of concomitant steroid therapy as 
premedication for the chemotherapy, and possible immune-suppressive effects 
of the repeated chemotherapy cycles (Krieg 2008).  
Overall, TLR9 agonists are generally well tolerated in patients with 
cancer. The most common adverse effects observed with administration of 
TLR9 agonists are local injection-site reactions (erythema, edema, 
inflammation and pain) or systemic flu-like symptoms (headache, rigors, 
pyrexia, nausea and vomiting). These symptoms typically develop with 24 h of 
dosing and are transient, generally lasting for less than 2 days (Krieg, 2006). 
Clinical trials are ongoing in other settings and in combination with other 
therapeutic approaches, and the true therapeutic potential of TLR9 agonists for 
the treatment of cancer remains to be further determined (Krieg 2008). 
Based on extensive structure activity relationship studies, second-
generation synthetic agonists of TLR9 containing 3’-3’-attached novel 
structures (immunomers) and immunomodulatory CpR (R=2’-deoxy-7-
dezaguanosine) dinucleotides, referred to as immune modulatory 
oligonucleotides (IMOs), have been synthesized. The rationale behind using 
3’-3’-attached DNA structure is that TLR9 reads DNA sequence from the 5’-
end and that an accessible 5’-end is required for its recognition. IMOs contain 
two accessible 5’-ends and have demonstrated distinct cytokine profiles in vitro 
and in vivo, compared with conventional TLR9 agonists and higher metabolic 
stability due to the novel structure present in them (Kandimalla et al. 2003; Yu 
et al. 2002). Previous studies have demonstrated potent antitumor activity of 
IMO-2048, containing a mouse-specific immunostimulatory sequence cross-
reacting with human TLR9, as monotherapies and in combination with 
chemotherapeutic agents and MAbs (Kandimalla et al. 2003; Damiano et al. 
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2006). Currently, a human analogue of this IMO, IMO-2055 (Idera 
Pharmaceuticals Inc., Cambridge, MA, USA), is under clinical evaluation in 
combination with chemotherapy and other agents in cancer patients. IMO-2055 
has been evaluated for its safety and immunological activity in Phase I studies 
involving healthy subjects and refractory cancer patients, and is being 
evaluated in phase I/II trial in combination with gemcitabine and carboplatin in 
patients with refractory solid tumors. Moreover, IMO-2055 is being evaluated 
at two dose levels, with subcutaneous administration, in a Phase II trial for 
metastatic or recurrent renal cell carcinoma (RCC).  The first part of the study 
(Stage A) including treatment naïve patients and patients who have received 
one prior therapy, has been completed. The primary objective, tumor response 
based on RECIST (Response Evaluation Criteria In Solid Tumors), was not 
achieved in the study. Median progression-free survival among the arms 
ranged from 2 to 4 months. IMO-2055 treatment was generally well-tolerated 
with good dose intensity in all arms of the study.  
Although the TLR9 immunologic mechanisms are fairly well 
understood and the clinical development of TLR9 agonists is very encouraging, 
the mechanisms by which they affect signalling proteins involved in tumor 
growth and angiogenesis, thus leading to tumor growth inhibition, are yet to be 
elucidated. We have hypothesized that the novel TLR9 agonists IMO could 
impair EGFR signalling. If this is the case, IMO could greatly enhance the 
activity of EGFR antagonists, including cetuximab, with an EGFR-dependent 
mechanism, additional to the possible boost of ADCC, which has been shown 
previously to be an important component of the antitumor activity of 
cetuximab (Clynes et al. 2000). Using IMO-2048 recognizing human and 
murine TLR9, we recently discovered that IMO acts by impairing EGFR 
signalling, cooperates with anti-EGFR drugs and boosts the ADCC of anti-
EGFR antibodies (Damiano et al. 2006). We have shown that IMO alone has 
an antitumor effect on GEO human colon cancer xenografts and that markedly 
inhibits the expression of EGFR ligand TGF-α, total and activated EGFR, 
activated pMAPK and pAkt, cyclooxygenase-2, and bcl-2, almost suppressing 
VEGF, without affecting its receptor VEGFR-2/KDR. Moreover, IMO causes  
about 30% inhibition of microvessel formation. Treatment with cetuximab 
caused an antitumor effect moderately better than IMO and, as expected from 
previous studies, accompanied by an inhibition of expression of the same 
signalling proteins although at a degree surprisingly lower than that obtained 
with IMO, whereas inhibition of microvessel formation was about 70%. When 
the two agents were used in combination, a potent cooperative antitumor effect 
was obtained, because a marked inhibition was still present 11 weeks after 
treatment withdrawal and tumors just recovered their growth rate. Moreover, 
the antitumor effect was accompanied by a marked inhibition or suppression of 
all the above proteins, including VEGFR-2/KDR, and an almost completely 
suppressed vessels formation. It should be noticed that the inhibition of these 
signalling proteins and of angiogenesis by IMO may be a valuable tool to 
prevent the occurrence of cetuximab resistance. We have also analyzed the 
 16
presence of tumor-infiltrating lymphocytes, which are considered a favorable 
prognostic factor in colorectal cancer (Compton et al. 2000). Both IMO and 
cetuximab induced an infiltration of the tumor by lymphocytes, but the 
combination of the two agents resulted in an impressive massive lymphocyte 
infiltration. The impairment of EGFR signalling and the consequences on 
growth and angiogenesis seem to represent a critical function of IMO. In fact, 
IMO in combination with the small-molecule EGFR tyrosine kinase inhibitor 
gefitinib, which is devoid of immunologic activity, showed again a cooperative 
antitumor effect and inhibition of critical signalling proteins although at a 
lesser degree compared to the combination with cetuximab. Remarkably, IMO 
alone was completely inactive against GEO-CR xenografts, an established 
cetuximab-resistant tumor xenograft, in which the ability to activate pAkt and 
downstream signalling becomes EGFR independent (Bianco et al. 2008). On 
the other hand, the EGFR-independent boosting of immunologic activity by 
IMO was helpful to unravel the non-EGFR-dependent activity of cetuximab. In 
fact, whereas cetuximab exhibited a modest activity on cetuximab-resistant 
GEO-CR xenografts likely due to ADCC, IMO plus cetuximab had a 
cooperative inhibitory effect, suggesting that IMO is able to boost the 
previously reported immunologic activity of cetuximab (Fan et al. 1993). These 
data further suggest that the antitumor effects observed with the combination 
are due part to the boost of immunologic properties of the MAb and part to the 
EGFR signalling. Finally, we have evaluated the antitumor activity of IMO in 
combination with cetuximab and the topoisomerase I–selective drug irinotecan, 
demonstrating that this drug combination is able to eradicate the tumors in 90% 
of animals without evidence of major side effects or organ toxicity in the 
pathologic examination. In conclusion, our study has shown for the first time 
that (a) IMO is able to interfere with the expression and function of a set of 
critical proteins related to EGFR signalling and involved in tumor cell 
proliferation, apoptosis, and angiogenesis; (b) this effect contributes to greatly 
enhance the antitumor activity of cetuximab, helping to dissect its mechanism 
of action; and (c) the combination of IMO with cetuximab and irinotecan has a 
potent antitumor activity producing a high rate of cure in mice bearing colon 
cancer xenografts (Damiano et al. 2006). These new findings have opened the 
path to clinical studies combining TLR9 agonists with EGFR inhibitors. An 
ongoing clinical trial in NSCLC is addressing the safety and potential clinical 
benefit of PF-3512676 combined with erlotinib (Krieg 2008). In December 
2007, a Phase Ib trial of IMO-2055 in combination with erlotinib and 
bevacizumab has been initiated in patients with NSCLC who have progressed 
on first line chemotherapy. A second Phase Ib clinical study of IMO-2055 in 
combination with cetuximab and irinotecan in patients with advanced 
colorectal cancer is planned.  
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2. AIM OF THE STUDY  
 
The recent findings on the major role played on tumor progression by 
host immune system and tumor microenvironment suggest that they may be 
critical factors also in the failure of targeted therapies. The yet lacking 
integration of these findings with the information guiding the clinical use of 
targeted drugs would fill a major gap, greatly improving the efficacy of 
targeted agents, reducing the chance for resistance and favouring the 
development of other effective drugs. It is now necessary to investigate the 
mechanisms of resistance to targeted agents and  to design new combined 
targeted treatments in a wider framework, taking into account also 
angiogenesis, tumor/host immune balance and microenvironment. 
The aim of this study is to provide new insights into the mechanism of 
action of the novel antitumor TLR9 agonist IMO on signalling and 
angiogenesis, in order to design optimal treatment combination and schedule 
strategies to be easily transferred into clinical practice. 
In the former study we observed a potent inhibitory effect of IMO and 
cetuximab on VEGF and angiogenesis in wild type but not in GEO-CR colon 
tumors, suggesting that the anti-VEGF effect may be only EGFR-dependent. 
Therefore, in this study we have studied whether: a) the potent inhibitory effect 
on VEGF and angiogenesis observed with IMO and cetuximab is mainly due to 
interference on EGFR pathway or it is independent; b) the dependance of IMO 
on an integral EGFR pathway may affect its combination with an anti-VEGF 
agent, such as bevacizumab; c) the ADCC mechanism is necessary to obtain a 
cooperative effect with MAbs. Therefore, we used IMO and the anti-VEGF 
antibody bevacizumab as tools to study IMO’s role on EGFR and angiogenesis 
and to explore its therapeutic potential in colon  cancer xenografts both 
sensitive and resistant to anti-EGFR drugs.  
Moreover, considering that IMO creates the opportunity to take 
advantage of multiple chance for cooperativity, involving EGFR- and ADCC-
dependent and -independent mechanisms and neoangiogenesis,  we have 
evaluated IMO ability to revert mechanisms of resistance to different targeted 
agents from EGFR inhibitors in different tumor models from colon cancer. 
Since intrinsic and acquired resistance to anti-ErbB2 antibody trastuzumab is 
becoming an increasingly relevant issue in breast cancer, we investigated 
whether the antitumor, antiangiogenic and immunostimulatory activity of IMO 
could enhance trastuzumab effect in trastuzumab-resistant breast cancers. 
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3. MATERIALS AND METHODS 
 
Compounds. IMO, 5’-TCTGACRTTCT-X-TCTTRCAGTCT-5’ (X 
and R are glycerol linker and 2’-deoxy-7-deazaguanosine, respectively), was 
synthesised with phosphorothioate backbone, purified and analyzed as 
described previously (Kandimalla et al. 2003). The anti-VEGF MAb 
bevacizumab was kindly provided by Genentech (South San Francisco, CA). 
The anti-ErbB2 MAb trastuzumab was kindly provided by Roche (Basel, 
Switzerland). 
 
Cell cultures. GEO, LS174T, GEO cetuximab-resistant (GEO-CR) 
(Ciardiello et al. 2004) colon cancer cells, BT474, KPL-4, JIMT-1 breast 
cancer cells and  HUVEC (human umbilical vein endothelial cells) were 
maintained respectively in McCoy’s or RPMI medium supplemented with 10% 
heat-inactivated fetal bovine serum, 20 mM HEPES, pH 7.4, penicillin (100 
UI/ml), streptomycin (100 µg/ml) and 4 mM glutamine (ICN, Irvine, UK) in a 
humified atmosphere of 95% air and 5% CO2 at 37° C.  
 
ADCC assay. Non-adherent fraction of human peripheral blood 
mononuclear cells (PBMCs) were used as effector cells. Briefly, human 
PBMCs were isolated by density gradient centrifugation and re-suspended in 
RPMI medium. Prior to the assay, the PBMCs were cultured 1 hour on plastic 
dishes to remove adherent cells (monocytes) and then the peripheral blood 
lymphocytes (PBLs) were incubated for 24 hours in presence or absence of 
IMO (5µM). The target cells (chronic erythroid leukemia K562 and breast 
cancer MDA468, JIMT-1 or KPL-4) were loaded with the fluorescence 
enhancing ligand (DELFIA BATDA reagent, PerkinElmer, Wellesley, MA) 
and, after washing, were incubated in presence or absence of antibodies 
bevacizumab, cetuximab or trastuzumab 10 µg/ml. Target cells were mixed 
with effector cells at varying cell concentration for 2 hours at 37°C and 
centrifuged. Supernatants were added to Europium solution and the signal was 
measured, as previously described (Blomberg et al. 1996).  
 
Xenografts in nude mice. Five weeks old Balb/cAnNCrlBR athymic 
(nu+/nu+) mice (Charles River Laboratories, Milan, Italy) were maintained in 
accordance with institutional guidelines of the University of Naples Animal 
Care Committee and in accordance to the Declaration of Helsinki. GEO, 
LS174T, GEO-CR, KPL-4 or JIMT-1 human cancer cells (107 cells/mice) were 
resuspended in 200 μL of Matrigel (Collaborative Biomedical Products, 
Bedford, MA) and injected subcutaneously (sc) in mice. After 7 days, tumors 
were detected and groups of 10 mice were randomized to receive the following 
treatments: intraperitoneal (ip) IMO, 1 mg/kg three times a week for 4 weeks; 
ip bevacizumab 5 mg/kg, twice a week for 3 weeks; ip trastuzumab 3,75 
mg/kg, twice a week for 3 weeks; or the combination of these agents, on days 
7-11, 14-18 and 21-25, continuing only IMO on days 28-32. Tumor volume 
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was measured using the formula π/6 x larger diameter x (smaller diameter)2 as 
previously reported (Ciardiello et al. 1996). Two mice were sacrificed on day 
25 to perform biochemical analysis. 
 
Immunoprecipitation and Western blot analysis. Total cell lysates 
were obtained from cellular lysates or homogenized tumor specimens removed 
on day 25. The protein extracts were resolved by 4-15% SDS-PAGE and 
probed with anti-human, polyclonal Akt, monoclonal pAkt, (Cell Signaling 
Technologies, Beverly, MA), monoclonal actin (Sigma-Aldrich, Milan), 
monoclonal pEGFR, polyclonal EGFR, polyclonal pErbB2, monoclonal 
ErbB2, monoclonal VEGF, monoclonal pMAPK and monoclonal MAPK 
(Santa Cruz, Santa Cruz, CA). Immunoreactive proteins were visualized by 
enhanced chemiluminescence (Pierce, Rockford, IL), as described previously 
(Ciardiello et al. 2004). Co-immunoprecipitation analysis were performed by 
immunoprecipitation using a monoclonal anti-TLR9 antibody 
(Calbiochem/EMD Biosciences, La Jolla, CA) and blotting with polyclonal 
anti-EGFR antibody or with monoclonal anti-ErbB2 antibody, following 
procedures described above.  
 
Elisa assay. Anti-hVEGF or anti-mVEGF polyclonal antibody (R&D 
Systems, Minneapolis, MN), diluted at 1 µg/ml in PBS, pH 7.5, was used to 
coat a 96-well plate, 100 µl/well, overnight at 4 °C. Washings, dilutions of 
standards (recombinant hVEGF or mVEGF) and samples (serum of sacrificed 
mice or conditioned media from cultured cells), biotinylation and mix with 
preformed avidin and biotinylated HRP macromolecular complex (Vectastain 
kit) were previously described (Errico et al. 2004). The absorbance was 
measured at 490 nm on a microplate reader (Bio-Rad, Hercules, CA). VEGF 
concentrations were determined by interpolation of the standard curve using 
linear regression analysis. 
 
Cell Survival Assay. Cells were grown in 24-well plates and exposed 
to drugs. The percentage of cell survival was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according 
to manufacturer’s instructions.  
 
Growth in soft agar Assay. Cells (104 cells/well) were suspended in 
0.3% Difco Noble agar (Difco, Detroit, MI) supplemented with complete 
medium, layered over 0.8% agar-medium base layer and treated with different 
concentrations of trastuzumab. After 10–14 days, cells were stained with nitro 
blue tetrazolium (Sigma Chemical Co., Milan, Italy) and colonies >0.05 mm 
were counted (Ciardiello et al. 2001). 
 
Adhesion assay.  96-microwell bacterial culture plates were precoated 
with 50 µl/well of serum-free medium containing 0.1% BSA (SFM, negative 
control) or Matrigel (1 mg/ml in water). After 1 hour, all coating solutions 
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were removed and  HUVECs (20,000 cells/well) were plated in SFM, in 
presence or absence of IMO 1 µM  After incubation cells were analyzed as 
previously described (Benelli et al. 2003). 
 
Wound healing assay. Monolayers of HUVEC cells were grown on 
gridded plastic dishes and scratched as previously reported (Bennett et al. 
2007) with or without doxorubicin 10 ng/ml or IMO 1 µM (0 h), which cause 
the same antiproliferative effect. Since doxorubicin did not interfere with cell 
migration, it was used as a negative control. The migration distances between 
the edges of the cells in the wound were photographed (10X magnification) at 
0 and 24 hours, quantified and compared using Adobe Photoshop ver 8.0.1 
(Bennett et al. 2007).   
 
Vascular endothelial cell capillary tube and network formation. 
Five hundred μl of diluted Matrigel was added into a 30-mm culture dish and 
incubated at 37°C for 30 min. After the Matrigel was solidified, HUVECs (4 × 
105) in 1 ml of RPMI medium were added in each dish, in presence or absence 
of IMO and/or trastuzumab, incubated at 37°C and photographed (10X) at 0 
and 24 hours, to monitor the process of vascular endothelial cell tube and 
network formation. As positive control, Matrigel was mixed with VEGF 100 
ng/ml (R&D Systems, Minneapolis, MN, USA). 
 
Immunofluorescence and confocal microscopy analysis. 5×104 
cells/ml were plated in complete medium on 12 mm diameter glass coverslips. 
48 hours later, cells were fixed and permeabilized, as previously described 
(Ulianich et al. 2008). Cells were then incubated for 1 hour with the primary 
antibodies diluted in 0.5% BSA (Sigma) in PBS: polyclonal rabbit anti-human 
EGFR (Santa Cruz, Santa Cruz, CA) and monoclonal mouse anti-human TLR9 
(Calbiochem/EMD Biosciences, La Jolla, CA). After three washes with 0.2% 
gelatin in PBS-CM, cells were incubated for 20 minutes with the appropriate 
rhodamine- or fluorescein-tagged goat anti-mouse or anti-rabbit antibody 
(Jackson ImmunoResearch, West Grove, PA), diluted 1:50 in 0.5% BSA in 
PBS. After final washes with PBS, the coverslips were mounted on a 
microscope slide and examined with a Zeiss 510 confocal laser scanning 
microscope. Samples were observed by three investigators, without knowledge 
of the experimental conditions. 
 
Statistical analysis. The Student’s t test was used to evaluate the 
statistical significance of the results. All reported P values were two-sided. All 
analyses were performed with the BMDP New System statistical package 
version 1.0 for Microsoft Windows (BMDP Statistical Software, Los Angeles, 
CA). 
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4. RESULTS AND DISCUSSION 
 
Bevacizumab has no ADCC activity and IMO is unable to affect it. 
Since bevacizumab binds the ligand and not the membrane receptor, we have 
verified whether it has any ADCC activity and whether IMO affects it. To 
investigate the capability of bevacizumab to activate an ADCC reaction in 
cancer cells and the influence of IMO in a combination treatment, we 
performed an in vitro cytotoxic assay using the conventional target MDA-468, 
a human breast cancer line which expresses both EGFR and VEGFRs. As 
expected, in the absence of antibodies, freshly isolated non-adherent human 
peripheral blood lymphocytes (PBLs) were able to kill the standard NK-target 
K562 cells, but did not induce any detectable lysis of MDA468 cells (Fig. 1). 
The same result was obtained when PBLs were incubated with IMO. 
Conversely, the anti-EGFR MAb cetuximab, that possesses a formerly 
described ADCC mechanism (Fan et al. 1993), caused a 40% induction of 
MDA-468 lysis. Pre-incubation of PBLs with IMO potentiated up to 60% of 
the MDA-468 killing induced by cetuximab (Fig. 1). On the contrary, pre-
incubation of PBLs with IMO did not affect the bevacizumab inability to 
produce the lysis of MDA-468 cells. In fact, bevacizumab as well as the 
combination of IMO and bevacizumab have no ADCC. Therefore, we have 
shown that while the basal ADCC activity of cetuximab is enhanced by IMO, 
thus contributing to cetuximab activity with an EGFR-independent mechanism, 
bevacizumab has no ADCC activity and IMO is unable to affect it. 
 
 
 
Fig. 1. ADCC Assay. The effector cells (human PBLs) were incubated in presence or 
absence of IMO and then mixed with the target cells (K562 and MDA468), which 
were incubated in presence or absence of the antibodies cetuximab and bevacizumab, 
at different effector/target ratio (E:T ratio). Doses and time of incubation are indicated 
in Materials and Methods Section. 
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Combination of bevacizumab with IMO synergistically inhibits 
GEO and LS174T colon cancer xenografts. BalbC nude mice xenografted 
with GEO and LS174T tumors were treated with IMO or bevacizumab, alone 
and in combination (Fig. 2A and 2B). On day 56, 8 weeks after tumor 
injection, all untreated mice xenografted with GEO cells reached the maximum 
allowed tumor size of about 2 cm3, while mice treated with IMO alone 
exhibited a 50% growth inhibition, having a size of  about 1 cm3. Treatment 
with bevacizumab produced a 35% inibition, since tumors measured 1.3 cm3 at 
the same time point. The combination of IMO plus bevacizumab caused a 
potent cooperative antitumor activity, with over 95% growth inhibition (tumor 
size of only 0.12 cm3) (Fig. 2A). Similar effects were observed in LS174T 
xenografts. The maximum allowed size of about 2 cm3 was reached on day 35 
in the untreated mice. On day 56, at the end of the experiment, mice treated 
with IMO or bevacizumab alone measured about 1.6 and 1 cm3, respectively, 
while in those treated with the two agents in combination showed a potent 
cooperative tumor growth inhibition of about 95% compared to untreated 
animals, resulting in a tumor size of 0.16 cm3 (Fig. 2B). No treatment-related 
side effects were observed in either tumor model. Comparison of tumor sizes 
among different treatment groups, evaluated by the Student’s t test, was 
statistically significant both in GEO and LS174T tumors (Fig. 2).  
 
 
 
 
 
Fig. 2. Cooperative effect of IMO and bevacizumab on tumor growth of mice bearing 
human colon cancer xenografts. After 7 days following tumor cell injection, mice 
were randomized (10/group) to receive IMO, bevacizumab or the combination, as 
indicated in Materials and Methods Section. The Student’s t test was used to compare 
tumor sizes among different treatment groups at day 56 following GEO (A) and 
LS174T (B) cell injection. They resulted statistically significant for IMO plus 
bevacizumab versus control (two sided P < 0.0001), versus IMO alone (two sided P < 
0.0001), and versus bevacizumab alone (two sided P < 0.0001) in both experiments. 
Bars, SD. 
 23
Combination of bevacizumab with IMO inhibits the expression of 
signalling proteins and angiogenesis in GEO and LS174T xenografts and 
reduces the levels of hVEGF, but not of mVEGF, in mice serum. We 
analyzed the effect of treatment on the expression of a variety of proteins 
playing a critical role in cancer cell proliferation and angiogenesis. Western 
blotting analysis was performed on cell lysates from tumors removed at the end 
of the third week of treatment, on day 25. As shown in Fig. 3A and 3B, IMO 
did not affect the total amount of MAPK and Akt, but inhibited their activated 
forms pMAPK and pAkt and the VEGF expression. Bevacizumab inhibited the 
same signalling proteins, although to a lesser degree compared to IMO. When 
the two agents were used in combination, a more potent inhibition was 
observed on protein expression. To confirm the effect of combination of 
bevacizumab with IMO on human VEGF levels, we performed ELISA on the 
serum obtained from LS174T bearing mice (Fig. 3C and D). Since 
bevacizumab recognizes only human VEGF, as expected it caused a reduction 
in the levels of circulating human VEGF (hVEGF) in the serum. The treatment 
with IMO alone reduced the secreted hVEGF levels and the combination with 
bevacizumab caused a more potent inhibition of circulating hVEGF levels 
compared to treatment with single agents (Fig. 3C). On the contrary, neither 
single agent nor the combination affected murine VEGF (mVEGF) compared 
to untreated mice (Fig. 3D).  Therefore, analysis of the secreted VEGF in the 
serum of sacrificed mice confirmed that bevacizumab, as expected, reduces the 
hVEGF levels and that also the combination of IMO and bevacizumab 
cooperates in reducing the levels of hVEGF, but not of mVEGF. These results 
suggest that the murine-dependent immune mediated effects of IMO enhance 
the activity of bevacizumab only on the human tumor cells.  
 
 
 
Fig. 3. Western blot analysis of GEO (A) and LS174T (B) tumors and ELISA on mice 
serum (C-D). Western blotting (A and B) was performed on total lysates from tumor 
specimens of two mice sacrificed on day 25. ELISA for hVEGF and mVEGF (C and 
D) were performed on serum of two mice sacrificed on day 25. Lane 1, Untreated 
control; lane 2, IMO; lane 3, bevacizumab; lane 4, IMO plus bevacizumab. 
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Combination of bevacizumab with IMO causes a potent antitumor 
activity in cetuximab resistant GEO-CR xenografts. We evaluated whether 
a cooperative effect could be obtained in cetuximab-resistant GEO-CR tumors, 
in the absence of an ADCC effect. We have shown that IMO alone is 
ineffective, while bevacizumab markedly inhibited GEO-CR growth (Fig. 4A). 
When IMO was used in combination with bevacizumab a cooperative 
inhibitory effect was observed, since at the end of the experiment, tumors were 
still about 0.15 cm3 (Fig 4A). With the exception of the mice treated with IMO 
alone, the Student’s t test demonstrated that the growth inhibition caused by 
each treatment in comparison to untreated mice as well as the tumor size 
among different treatment groups were statistically different (Fig. 4). Western 
blotting analysis of protein extracts from GEO-CR tumors did not reveal any 
substantial changes in the expression of pAkt, pMAPK and VEGF in tumor 
specimens treated with IMO alone, while a marked inhibition was seen in those 
treated with bevacizumab or with the combination IMO plus bevacizumab 
(Fig. 4B).  
 
 
 
 
 
 
Fig. 4. Effect of the combination of IMO with bevacizumab in mice bearing 
cetuximab-resistant GEO-CR tumor xenografts. (A) After 7 days following GEO-CR 
tumor injection mice were randomized (10/group) to receive IMO, bevacizumab or the 
combination, as indicated in Materials and Methods Section. Inhibition of growth was 
significantly different in the IMO plus bevacizumab-treated group versus the control 
group, the IMO alone group and the bevacizumab alone group (two sided P < 0.0001 
for each comparison). Bars, SD. (B) Western blotting was performed on total lysates 
from tumor specimens of two mice sacrificed on day 25. Lane 1, Untreated control; 
lane 2, IMO; lane 3, bevacizumab; lane 4, IMO plus bevacizumab.  
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Therefore, we have demonstrated that combination of bevacizumab with IMO 
is active also in anti-EGFR resistant tumors in an ADCC-independent fashion, 
suggesting that other mechanisms, not strictly EGFR- and ADCC-dependent, 
take place. In support of this notion, the two agents in combination 
cooperatively inhibit the expression of proteins used by tumors as escape 
pathways to acquire resistance to targeted therapies, such as pMAPK, pAkt and 
VEGF (Bianco et al. 2005) and inhibit neoangiogenesis in all three tumor 
types.  
 
 
IMO inhibits survival, adhesion to matrix, migration and capillary 
formation capability of human endothelial cells.  An important mechanism 
of antiangiogenic therapy is the blockade of the VEGF-dependent proliferation 
of endothelial cells in the tumor. In an attempt to provide a clue to explain the 
non EGFR-dependent cooperative antiangiogenic effects obtained with IMO 
and bevacizumab, we measured IMO activity on several functions of 
endothelial cells. We performed a cell survival assay on HUVEC cells. At 
doses of 1 and 5 µM, IMO caused a moderated inhibition of HUVEC cell 
survival, which was increased by the addition of lipofectamine, an agent that 
facilitates cellular uptake of IMO (Fig. 5A). We then analyzed the effects of 
IMO on HUVEC cell adhesion and migration using a cell adhesion assay to 
matrigel and a wound healing assay. At 1 µM concentration, IMO showed a 
potent inhibitory activity on adhesion and migration of endothelial cells (Fig. 
5B and C).  Finally, we examined the effects of IMO on VEGF-stimulated 
capillary tube and network formation and observed that this process is strongly 
inhibited by IMO (Fig. 5 D). Therefore, we demonstrated for the first time that 
IMO inhibits proliferation, adhesion and migration of HUVEC endothelial cells 
and, importantly, the VEGF-stimulated capillary tube and network formation. 
It is likely that the well documented inhibitory effect of bevacizumab on 
vessels formation, due to VEGF inhibition, combined with the interference of 
IMO on critical functions of tumor endothelial cells, may finally be responsible 
for the cooperative effect observed. In addition, since it has been reported that 
colon cancer cell lines, including GEO, express VEGFRs (Fan et al. 2005), the 
combined effect of IMO and bevacizumab may have a direct impact also on 
tumor cells. Altogether these data may also help to explain, at least in part, the 
hemorragic necrosis observed in the LS174T tumors.  Since IMO is able to 
directly inhibit in vitro endothelial cells functions, we have suggested that, 
beside the immune activation, TLR9 agonists have a much broader range of 
mechanisms, involving not only the EGFR-dependent pathway but also the 
neoangiogenesis. It has been demonstrated that tumor microenvironment is a 
complex system made of many cell types participating in tumor progression 
and including endothelial cells and their precursors, pericytes, fibroblasts, 
granulocytes, mast cells, T, B and natural killer (NK) lymphocytes, and 
antigen-presenting cells such as macrophages and dendritic cells (DCs). 
Moreover, recent evidence shows that complex endothelial-immune  cell cross-
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talk regulate vessel function and that multiple immune cells polarizations are 
involved in a dichotomous activity towards angiogenesis induction or 
inhibition. The factors imposing immune cell polarization appear to be a 
function of the microenvironment (Noonan et al. 2008). In this respect, it could 
be interesting to study IMO anti-angiogenic effect also on other cells of 
tumoral/microvascular microenvironment and to evaluate IMO potential 
activity on these pro-or anti-angiogenic polarizations. 
 
 
 
Fig. 5. IMO effects on HUVEC cell survival (A), adhesion to matrix (B), migration 
(C), and tube formation (D). (A) HUVEC cells were treated with IMO in presence or 
absence of Lipofectamine (2 µg/ml). The results are statistically significant for each 
dose of IMO versus control (two sided P<0.0001). (B) HUVEC cells plated in 
presence or absence of IMO 1 µM in serum-free medium (negative control) or 
Matrigel. The results are statistically significant for Matrigel versus negative control 
and for IMO versus Matrigel (two sided P<0.0001). (C) HUVEC cells monolayers 
were wounded in absence or presence of doxorubicin 10 ng/ml or IMO 1 µM (0h). 
The results are statistically significant for IMO versus control and versus doxorubicin 
(two sided P<0.0001). (D) HUVEC cells were incubated on diluted Matrigel in 
presence or absence of IMO 1 μM. Matrigel mixed with VEGF 100 ng/ml was used as 
positive control. Photographs were taken at 0 and 24 hours. 
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Trastuzumab is unable to inhibit growth and ErbB-related 
signalling pathway in KPL-4 and JIMT-1 human breast cancer cell lines. 
Considering that IMO creates the opportunity to take advantage of multiple 
chance for cooperativity, involving EGFR- and ADCC-dependent and -
independent mechanisms and neoangiogenesis,  we have evaluated IMO ability 
to revert mechanisms of resistance in different tumor models from colon 
cancer. Since intrinsic and acquired resistance to anti-ErbB2 antibody 
trastuzumab is becoming an increasingly relevant issue in breast cancer, we 
investigated whether the antitumor, antiangiogenic and immunostimulatory 
activity of IMO could enhance trastuzumab effect in trastuzumab-resistant 
breast cancers. To this aim, we have identified/selected human breast cancer 
cell lines with different sensitivity to trastuzumab (Kurebayashi et al. 1999; 
Tanner et al. 2004). As shown in Figure 6A, we have verified in a soft agar cell 
growth assay that BT474 cells are sensitive to trastuzumab (IC50 <0.1 µg/ml), 
while KPL-4 and JIMT-1 are insensitive to trastuzumab at doses up to 50 
µg/ml. In fact, KPL-4 and JIMT-1 are described as two human estrogen 
receptor-negative and ErbB2-overexpressing breast carcinoma cell lines, 
recently established as experimental models for the study of new trastuzumab-
resistance mechanisms. KPL-4 cell line was isolated from the malignant 
pleural effusion of a breast cancer patient with an inflammatory skin metastasis 
(Kurebayashi et al. 1999). JIMT-1 cell line was established from a pleural 
metastasis of a 62-year old patient with breast cancer who was clinically 
resistant to trastuzumab (Tanner et al. 2004). On BT474, KPL-4 and JIMT-1 
cells, we have evaluated the expression levels of EGFR and ErbB2. All cells 
show similar levels of EGFR expression while ErbB2 levels are higher in KPL-
4 and JIMT-1 than in BT474 cells. Moreover, we have demonstrated that KPL-
4 cells overexpress the NH2 terminally truncated ErbB2 receptor, p95ErbB2 
(Fig. 6B), that has been correlated to trastuzumab.resistance in breast tumors 
(Scaltriti et al. 2007). We have compared for the first time the effect of 
trastuzumab on the activation of ErbB signal transduction, in cancer cells 
sensitive and resistant to trastuzumab. We have demonstrated that trastuzumab 
is able to inhibit the activation of signalling proteins critical for cancer cell 
proliferation, survival and angiogenesis in sensitive but not in resistant cell 
lines. In fact, as shown in fig. 6C, trastuzumab reduces the  
phosphorylation/activation of MAPK and Akt in BT474 cell line but not in 
KPL-4 and JIMT-1 cell lines. Similarly, trastuzumab inhibits the secretion of 
the main pro-angiogenic factor VEGF in BT474 cells but is totally ineffective 
in KPL-4 and JIMT-1 cells (Fig. 6D).  
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Fig. 6. Characterization of human breast cancer cell lines sensitive or resistant to 
trastuzumab. (A) Effects of trastuzumab on the soft agar growth of BT474, KPL-4 and 
JIMT-1 cells. Cells were treated with the indicated concentrations of trastuzumab each 
day for 3 consecutive days. Colonies were counted after 10–14 days. Data represent 
the mean (±SD) of three independent experiments, each performed in triplicate, and 
are presented relative to untreated control cells. The effects of trastuzumab were 
statistically significant versus control for BT474 cell line (2-sided P<0.0001), but not 
for KPL-4 and JIMT-1 cell lines. (B) Western blot analysis of EGFR and ErbB2 
protein expression on total cell lysates from BT474, KPL-4 and JIMT-1 cell lines. (C) 
Western blotting on total cell lysates from cells treated with 5μg/ml  trastuzumab. 
Lane 1: untreated control; lane 2: trastuzumab. (D) ELISA assays for hVEGF on 
conditioned media from cancer cells treated with trastuzumab (5μg/ml) each day for 3 
consecutive days. Data represent the mean (±SD) of three independent experiments, 
each performed in triplicate. The effects of trastuzumab were statistically significant 
versus control for BT474 cell line (2-sided P<0.0001), but not for KPL-4 and JIMT-1 
cell lines. 
 
 
Combination of trastuzumab with IMO synergistically inhibits 
KPL-4 and JIMT-1 breast cancer xenografts. We have evaluated IMO 
capabilities to inhibit the growth and to enhance the activity of trastuzumab on 
KPL-4 and JIMT-1 xenografts. BalbC nude mice xenografted with KPL-4 or 
JIMT-1 tumors were treated with IMO or trastuzumab, alone and in 
combination (Fig.7). On day 56, 8 weeks after tumor injection, all untreated 
mice xenografted with KPL-4 or JIMT-1 cells reached the maximum allowed 
tumor size of about 2 cm3. Treatment with trastuzumab produced a similar 
effect in both tumor models, causing on day 49, 3 weeks after treatment 
withdrawal, about 75% and 65% inhibition in KPL-4 and JIMT-1 tumor 
growth, respectively. However, starting from this time point, tumors treated 
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with trastuzumab alone resumed an exponential growth, reaching 2 cm3 tumor 
size on day 98. Our data agree with a recent report demonstrating that 
trastuzumab is able to inhibit the outgrowth of macroscopically detectable 
JIMT-1 xenografted tumors despite the intrinsic resistance to trastuzumab in 
vitro and that this effect is likely to be mediated via ADCC (Barok et al. 2007); 
however, about three weeks after treatment withdrawal, tumors treated with 
trastuzumab resum an exponential growth, therefore at this time point 
trastuzumab is able only to reduce the number of circulating and disseminated 
tumor cells (CTCs and DTCs) but no more to inhibit the growth of primary 
tumor (Barok et al. 2008). IMO treatment inhibited tumor growth both in KPL-
4 and in JIMT-1 xenografts, that reached the 2 cm3 tumor size on day 77 and 
day 84, respectively. The combination of IMO plus trastuzumab caused a 
potent and long-lasting cooperative antitumor activity, with 75% growth 
inhibition (tumor size of 0.5 cm3) until the end of the experiment, on day 105, 
11 weeks after treatment withdrawal. No treatment-related side effects were 
observed in either tumor model studied. Comparison of tumor sizes among 
different treatment groups, evaluated by the Student’s t test, was statistically 
significant both in KPL-4 and JIMT-1 tumors (Fig. 7A and 7B). The median 
survival of mice treated with IMO or trastuzumab was 8 and 9,5 weeks, 
respectively, compared with 5,5 weeks in control mice. Difference among the 
groups were calculated by log-rank test. IMO plus trastuzumab group did not 
reach a median survival, since 80% of the mice were still alive at the end of the 
esperiment (Fig. 7C and 7D). Interestingly, the mechanisms involved in 
trastuzumab resistance of KPL-4 and JIMT-1 human breast cancer cell models 
are different. KPL-4 overexpress p95ErbB2, the amino terminally truncated 
carboxyl terminal fragment of ErbB2, known also as C-terminal fragment, 
frequently found in ErbB2-expressing breast cancer cell lines and tumors and 
related to poor clinical outcome as well as reduced effectiveness of some 
therapeutic treatments. In particular, the presence of p95ErbB2 has been 
associated with trastuzumab-resistance. In fact, it has been shown that cells 
stably expressing p95ErbB2 are resistant to trastuzumab but remain sensitive to 
the antiproliferative effects of the TKI lapatinib, both in vitro and in vivo. 
Furthermore, in a series of patients with ErbB2-positive advanced breast cancer 
who were treated with trastuzumab, the presence of p95ErbB2 is associated 
with clinical resistance to trastuzumab, whereas tumors expressing only the 
full-length receptor exhibit a high response rate to trastuzumab (Scaltriti et al. 
2007). Moreover, it has been suggested that trastuzumab resistance may be 
mediated in part by the selection of p95ErbB2-expressing breast cancer cells 
capable of exerting potent growth and prosurvival signals through p95ErbB2-
ErbB3 heterodimers (Xia et al. 2004). Conversely to KPL-4, JIMT-1 cell line 
shows a decreased  accessibility of ErbB2 and a diminished trastuzumab 
binding due to the expression of MUC4, a membrane-associated mucin that 
contributes to the partial masking of ErbB2. In fact, if the expression profile of 
ErbB proteins and trastuzumab-induced ErbB2 internalization/down-regulation 
in JIMT-1 are similar to those in trastuzumab-sensitive lines, the mean number 
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of trastuzumab binding sites in JIMT-1 is 1/5 that of the expressed ErbB2 
molecules, although 5% to 10% of the cells showed a approximately 10-fold 
higher trastuzumab binding than the main population. The expression of 
MUC4 is higher in JIMT-1 than in trastuzumab-sensitive lines and knockdown 
of MUC4 expression by RNA interference increased the binding of 
trastuzumab (Nagy et al. 2005). Our data have demonstrated that the 
combination of IMO plus trastuzumab caused a potent and long-lasting 
cooperative antitumor activity, until the end of the experiment, 11 weeks after 
treatment withdrawal, when 80% of the mice were still alive. This potent effect 
is similar both in KPL-4 and in JIMT-1 xenograft models demonstrating the 
strong therapeutic impact of the IMO-trastuzumab combination regardless to 
the mechanism of trastuzumab resistance.  
 
 
 
Fig. 7. Cooperative effect of IMO and trastuzumab on tumor growth (A and B) and 
survival (C and D) of mice bearing KPL-4 or JIMT-1 human breast cancer xenografts. 
After 7 days following tumor cell injection, mice were randomized (10/group) to 
receive IMO, trastuzumab or the combination, as indicated in Materials and Methods 
Section. The Student’s t test was used to compare tumor sizes among different 
treatment groups at day 56 following KPL-4 (A) and JIMT-1 (B) cell injection. They 
resulted statistically significant for IMO plus trastuzumab versus control (two sided P 
< 0.0001), versus IMO alone (two sided P < 0.0001), and versus trastuzumab alone 
(two sided P < 0.0001) in both experiments. Bars, SD. Both in KPL-4 (C) and in 
JIMT-1 (D) xenografted mice, median survival was 5,5 weeks in untreated mice, 8 
weeks in IMO-treated group (log-rank test versus controls; P < 0.0001), and 9,5 weeks 
in trastuzumab-treated group (log-rank test versus controls; P < 0.0001). No median 
survival could be calculated for IMO plus trastuzumab group. Bars, SD. 
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IMO, alone or in combination with trastuzumab, inhibits the 
expression of signalling proteins in KPL-4 and JIMT-1 xenografts. We 
analyzed the effect of treatment on the expression of a variety of proteins 
playing a critical role in cancer cell proliferation and angiogenesis. Western 
blotting analysis was performed on cell lysates from tumors removed at the end 
of the third week of treatment, on day 25. In KPL-4 tumors, IMO induced a 
moderate  reduction of phospho-EGFR and a more pronounced reduction of 
phospho-ErbB2. Moreover, IMO strongly inhibited the activated forms of 
MAPK and Akt as well as the VEGF expression. This signalling inhibition was 
not observed with trastuzumab treatment, indeed trastuzumab seemed to induce 
a slight activation of EGFR- and ErbB2-dependent signal transduction. IMO in 
combination with trastuzumab suppressed trastuzumab-induced signalling 
activation, producing a moderate inhibition compared to control. No treatment 
affected the total amount of EGFR, ErbB2, MAPK and Akt (Fig. 8A). In 
JIMT-1 tumors IMO did not affect the phosphorylation/activation of EGFR, 
ErbB2 and their downstream effectors, while trastuzumab weakly inhibited the 
same signalling proteins. When the two agents were used in combination, a 
potent inhibition was observed on protein expression, with an almost total 
suppression of phosphorylation/activation of EGFR, MAPK, Akt and VEGF. 
The combination  of IMO with trastuzumab also reduced the total amount of 
ErbB2 rather than the phospho-ErbB2 expression levels (Fig. 8B). 
 
 
 
Fig. 8. Western blot analysis of KPL-4 (A) and JIMT-1 (B) tumors. Western blotting 
was performed on total lysates from tumor specimens of two mice sacrificed on day 
25. Lane 1, Untreated control; lane 2, IMO; lane 3, trastuzumab; lane 4, IMO plus 
trastuzumab.  
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IMO enhances ADCC activity of trastuzumab on KPL-4 and 
JIMT-1 cells. To investigate the capability of trastuzumab to activate an 
ADCC reaction in KPL-4 and JIMT-1 cells cancer cells and the influence of 
IMO in a combination treatment, we performed a cytotoxic assay using as 
targets both cell lines. As expected, in the absence of antibodies, freshly 
isolated non-adherent human PBLs were able to kill the standard NK-target 
K562 cells, but did not induce any detectable lysis of KPL-4 or JIMT-1 cells 
(Fig. 9A and 9B). Similar results were obtained when PBLs were incubated 
with IMO. Conversely, trastuzumab, that possesses a formerly described 
ADCC mechanism (Mimura et al. 2005), caused a 85% induction of KPL-4 
lysis (Fig. 9A), and a 35% induction of JIMT-1 lysis (Fig. 9B). This difference 
could be explained on the basis of the lower ErbB2 expression levels and the 
masking of the receptor by the membrane-associated mucin MUC4 in JIMT-1 
(Nagy et al. 2005). Pre-incubation of PBLs with IMO potentiated KPL-4 and 
JIMT-1 cells killing induced by trastuzumab (Fig. 9A and 9B). Therefore, IMO 
potentiates trastuzumab-mediated ADCC on KPL-4 and JIMT-1 cells in vitro. 
Moreover, since it has been demonstrated that VEGF partially inhibits the 
ADCC of human monocytes mediated by trastuzumab, and this inhibition is 
mainly mediated by VEGFR1/Flt-1 (Mimura et al. 2007), the reduction of 
human VEGF levels induced by IMO could overcome such interference and 
further explain IMO-mediated potentiation of trastuzumab ADCC in vivo. 
 
 
 
 
 
 
 
 
Fig. 9. ADCC assay on KPL-4 (A) or JIMT-1 (B) cells. The effector cells (human 
PBLs) were incubated in the presence or absence of IMO and then mixed with the 
target cells (K562 and KPL-4 or JIMT-1), which were incubated in the presence or 
absence of trastuzumab, at different effector/target ratio (E:T ratio). Doses and time of 
administration are indicated in Materials and Methods Section. 
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TLR9 is expressed in KPL-4 cells and seems to functionally interact 
with EGFR. Since in KPL-4 tumors IMO strongly inhibited ErbB-dependent 
signal transduction in vivo, we investigated whether this effect could be related 
to a direct modulation of ErbB-dependent signalling. Therefore, we examined 
the effect of IMO on KPL-4 cells grown in vitro. To investigate  the potential 
functional/structural  relationship between TLR9 and ErbB family receptors, 
and the role played by IMO, we performed a co-immunoprecipitation 
experiment. We immunoprecipitated KPL-4 cell lysates with the anti-TLR9 
antibody and blotted with the anti-ErbB2 antibody or the anti-EGFR antibody. 
As the positive control, total proteins from KPL-4 cells were used; as the 
negative control, lysis buffer was mixed with monoclonal anti-TLR9 antibody. 
Therefore, we have demonstrated that ErbB2 and TLR9 co-
immunoprecipitated but this interaction was only slightly affected by IMO 
treatment. Instead, EGFR and TLR9 co-immunoprecipitated and the observed 
interaction was strongly reduced after 1 hour of IMO treatment (Fig. 10A). 
Since we have shown an IMO-modulated interaction between TLR9 and 
EGFR, we performed an immunofluorescence and confocal microscopy 
analysis for EGFR and TLR9 on KPL-4 cells in order to further analyze the 
intracellular relationship between the two receptors. As expected, EGFR was  
prevalently localized on cell membranes, while TLR9 seemed widely 
distributed both in intracellular compartments and in juxtramembrane regions. 
Therefore, we observed a partial co-localization of EGFR and TLR9 in the 
merge staining (Fig. 10B). TLR9 distribution observed in KPL-4 cells is 
different from the distribution described in immune cells. In fact, it has been 
shown that human TLR9, both endogenously expressed in B cells or 
transfected in immortalized cell lines, are retained in the ER before CpG 
exposure and that, following treatment with TLR9 agonists, a special 
mechanism must exist for translocating TLR9 to the signalling compartments 
that contain the agonists. However, the same authors did not rule out that TLR9 
may reside in a different cellular compartment depending upon the cell type 
examined, as previously described also for TLR4 (Leifer et al. 2004). 
Moreover, it has been shown that human intestinal epithelial cells respond to 
pathogenic bacterial DNA by increasing expression and surface localization of 
TLR9 (Ewaschuk et al. 2007). Finally we have verified whether IMO ability to 
modulate EGFR-TLR9 interaction could eventually produce an inhibition of 
EGFR signalling. As shown in Fig. 10C, IMO reduced the EGF-induced 
phosphorylation/activation of MAPK on KPL-4  in vitro, suggesting that IMO 
could directly affect EGFR signalling.  
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Fig. 10. Potential interaction between TLR9 and EGFR in vitro. (A) 
Immunoprecipitation using an anti-TLR9 antibody and blotting with an anti-ErbB2 or 
an anti-EGFR antibody on KPL-4 cells cultured in complete medium and treated for 1 
hour with 1 µM IMO. Lane 1, positive control; lane 2, untreated control; lane 3, 
treatment with IMO; lane 4, negative control. (B) KPL-4 cells were grown on glass 
coverslips for 48 hours, then were double stained with anti-TLR9 and anti-EGFR 
primary antibodies and incubated with the appropriate rhodamine- or fluorescein-
tagged goat anti-mouse or anti-rabbit antibody.  (C) Western blot analysis of protein 
expression in KPL-4 cells cultured in serum free medium, treated for 1 hour with 1 
µM IMO, and stimulated for 15 minutes with EGF 50 ng/ml before protein extraction. 
Lane 1, unstimulated and untreated control; lane 2, stimulation with EGF; lane 3, 
treatment with IMO and stimulation with EGF. 
 
 
Many interactions between EGFR and TLRs have been recently described; 
however, EGFR potential role in regulating human TLRs is not yet completely 
clarified. It has been demonstrated that EGFR acts as a negative regulator for 
TLR2 induction by the bacterium nontypeable Haemophilus influenzae (NTHi) 
via an Src-MKK3/6-p38 alpha/beta MAP kinase-dependent mechanism, 
attenuating host immune response. A NTHi-derived EGF-like factor appears to 
be responsible for the Direct activation of EGFR (Mikami et al. 2005). EGFR 
has been involved also in the induction of TLRs expression. It has been shown 
that lipid–pDNA complexes signal via EGFR-Erk to induce expression of 
TLR4 and TLR2, leading to an amplified inflammatory response after receptor 
engagement by PAMPs. EGFR inhibitor AG1478 completely inhibits pDNA-
mediated upregulation of TLR4/2 levels and associated IL-8 release in 
response to TLR4/2 agonists (Liu et al. 2008). Moreover, multiple TLR ligands 
have shown to induce airway epithelial cell production of IL-8 and VEGF via a 
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signalling cascade involving EGFR. In fact, ligands for TLR 1, 2, 3, 5, and 6, 
bind to their receptors, activating Dual oxidase 1 (Duox1) with the consequent 
generation of reactive oxygen species (ROS). TNF-alpha-converting enzyme 
(TACE), activated by ROS, cleaves a proligand, releasing soluble TGF-α 
which binds to and activates EGFR, initiating signalling for IL-8 and VEGF 
production (Koff et al. 2008). Interestingly, we have demonstrated for the first 
time that TLR9 seems to functionally interact with EGFR and that this 
interaction is modulated by the TLR9 agonist IMO, eventually producing an 
inhibition of EGFR signalling in KPL-4 cells. The existence of a potential 
TLR9 coreceptor has been suggested previously (Sanjuan et al. 2006). The 
authors proposed that the recognition of A class CpG-DNA is a two-step 
process that can begin at the plasma membrane by a TLR9-independent 
mechanism. CpG-DNA stimulation of a CpG-sensing membrane receptor 
would activate two Src family Kinases (SFKs), Hck and Lyn, that would 
initiate a tyrosine phosphorylation cascade. One downstream effector of the 
SFK pathway, Syk, interacts with TLR9. The second CpG-induced activation 
event occurs at the endosome when internalized CpG-DNA binds TLR9 and 
initiates the MyD88-dependent cascade. Chloroquine, an inhibitor of CpG-
triggered cytokine secretion, blocked TLR9/MyD88-dependent cytokine 
secretion as expected but failed to inhibit CpG-induced SFK activation and its 
dependent cellular responses. According to this view and to our data, it could 
be suggested a role for EGFR as the potential TLR9 coreceptor in cancer cells 
but further investigations are needed in order to dissect all the relationships 
between EGFR and TLR9. 
 
 
Combination of IMO plus  trastuzumab causes a direct 
antiangiogenic effect. To evaluate whether the strong cooperative effect of 
IMO plus trastuzumab combination on the growth of tumor xenografts could 
involve  a direct antiangiogenic activity, we performed a cell survival assay 
and a capillary tubes and network formation assay on HUVEC cells. We 
confirmed our previous observation of  IMO effects on HUVEC functions 
(Damiano et al. 2007), and demonstrated for the first time that also trastuzumab 
exhibits a direct antiangiogenic effect inhibiting both HUVEC survival (20% 
inhibition) and capillary formation capability. As shown in figure 11A, the 
combination of IMO and trastuzumab was more efficient in inhibiting HUVEC 
survival than the single agents. The VEGF-stimulated capillary tubes and 
network formation was  almost totally suppressed by the combined treatment 
(Fig. 11B). Several reports have described the expression of both EGFR and 
ErbB2 receptors on HUVEC (Bueter et al. 2006; Russell et al. 1999) and a 
recent study has also suggested that the expression of TGF-alpha by tumor 
cells leading to the activation of EGFR in tumor-associated endothelial cells is 
a major determinant for the susceptibility of neoplasms to therapy by specific 
EGFR-TKIs (Kuwai et al. 2008). Therefore, we have verified whether the 
effect of IMO and trastuzumab on HUVEC functions could be related to a 
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direct inhibition of EGFR-ErbB2 signalling. We have demonstrated that IMO 
inhibits the EGF-induced phosphorylation/activation of EGFR, ErbB2, Akt and 
MAPK. Interestingly, also trastuzumab is able to inhibit to a similar extent the 
same signalling proteins and, when the two agents were used in combination, a 
more potent inhibition or complete suppression is observed on the expression 
of the proteins affected by each single agent (Fig. 11C). Therefore, our data 
demonstrate for the first time that trastuzumab exhibits a direct antiangiogenic 
effect inhibiting both endothelial cell survival and capillary formation 
capability. Therefore, the combination with IMO and trastuzumab produces a 
cooperative direct anti-angiogenic effect, also related to a direct inhibition of 
EGFR-ErbB2 signalling in endothelial cells. 
 
 
 
Fig. 11. Effects of IMO and trastuzumab on HUVEC cell survival (A), tube formation 
(B) and signal transduction (C). (A) HUVEC cells were treated with IMO 1 μM, 
trastuzumab 5 μg/ml, or the combination of these agents. The results are statistically 
significant for IMO, trastuzumab, and the combination versus control (two sided P < 
0.0001). Lane 1, Untreated control; lane 2, IMO; lane 3, trastuzumab; lane 4, IMO 
plus trastuzumab. (B) HUVEC cells were added on matrigel in presence or absence of 
1 μM IMO, 5 μg/ml trastuzumab, or the combination of these agents. As the positive 
control, the Matrigel was mixed with 100 ng/ml of VEGF. Photographs were taken at 
0 and 24 hours. (C) Western blot analysis of protein expression in HUVEC cells 
cultured in serum free medium, treated for 1 hour with 1 µM IMO and/or for 24 hours 
with trastuzumab 5 µg/ml and stimulated for 15 minutes with EGF 50 ng/ml before 
protein extraction. Lane 1, unstimulated and untreated control; lane 2, stimulation with 
EGF; lane 3, treatment with IMO; lane 4, treatment with trastuzumab; lane 5, 
combined treatment with IMO and trastuzumab.  
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5. CONCLUSIONS 
 
TLR9 agonists are a novel class of compounds with potent antitumor 
activity that have entered the clinical evaluation in cancer patients. However, 
the mechanisms by which they affect growth signalling and angiogenesis are 
yet poorly understood. We have recently demonstrated that a novel antitumor 
TLR9 agonist (IMO) acts via EGFR and cooperates with anti-EGFR MAb 
cetuximab or TKI gefitinib, synergistically inhibiting colon tumor xenografts 
growth and angiogenesis. Conversely, IMO is inactive against cetuximab-
resistant tumors, further suggesting its dependance on EGFR signalling. 
We have aimed to provide new insights into the mechanism of action of 
IMO on signalling and angiogenesis, in order to design optimal treatment 
combinations to be easily transferred into clinical practice. In order to analyze 
whether the potent inhibitory effect obtained with IMO and EGFR inhibitors 
on angiogenesis was dependent or independent on the interference in the EGFR 
pathway, we have studied the combination of IMO and anti-VEGF MAb 
bevacizumab. We have demonstrated that IMO synergizes potently with 
bevacizumab in cancer xenografts sensitive and resistant to anti-EGFR drugs, 
in spite of the fact that IMO is unable to influence the lack of ADCC activity of 
bevacizumab. Moreover, IMO inhibits survival, adhesion, migration, and 
capillary tubes formation capability of human endothelial cells and it is likely 
that this property may finally be responsible for the cooperative effect observed 
also in EGFR-resistant models. To evaluate IMO ability to revert mechanisms 
of resistance in different tumor models, we have analyzed the combination of 
IMO with the anti-ErbB2 MAb trastuzumab, demonstrating that IMO strongly 
synergizes with trastuzumab producing a potent and long-lasting growth 
inhibition of trastuzumab-resistant breast cancer xenografts. The synergism is 
related not only to the potentiation of trastuzumab-induced ADCC, but also to 
the direct antitumor activity of IMO, explained also through a functional 
modulation of ErbB-mediated signalling, and to the direct cooperative 
antiangiogenic activity of the drug combination. Therefore, we demonstrate 
that the antitumor, antiangiogenic and immunostimulatory activity of IMO 
enhances trastuzumab effect in trastuzumab-resistant breast cancers, suggesting 
that IMO plus trastuzumab treatment could be an effective therapeutic strategy 
in breast cancers.  
This study provides new insights into the mechanisms of action of 
TLR9 agonists. In fact, it demonstrates that, although dependent on the 
immune activation, IMO has a much broader range of mechanisms, involving 
not only the EGFR-dependent pathway but also the neo-angiogenesis. These 
results provide a strong rationale to translate the combination with 
bevacizumab or trastuzumab into the clinical practice, as a potentially powerful 
and rationally-based therapeutic strategy. The possibility to combine IMO with 
inhibitors of EGFR, ErbB-2 and VEGF, creates the opportunity to take 
advantage of multiple chance for cooperativity, involving EGFR- and ADCC-
dependent and -independent mechanisms and neoangiogenesis. 
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Synthetic agonists of Toll-like receptor 9 (TLR9), a class of agents
that induce specific immune response, exhibit antitumor activity
and are currently being investigated in cancer patients. Intrigu-
ingly, their mechanisms of action on tumor growth and angiogen-
esis are still incompletely understood. We recently discovered that
a synthetic agonist of TLR9, immune modulatory oligonucleotide
(IMO), acts by impairing epidermal growth factor receptor (EGFR)
signaling and potently synergizes with anti-EGFR antibody
cetuximab in GEO human colon cancer xenografts, whereas it is
ineffective in VEGF-overexpressing cetuximab-resistant GEO
cetuximab-resistant (GEO-CR) tumors. VEGF is activated by EGFR,
and its overexpression causes resistance to EGFR inhibitors. There-
fore, we used IMO and the anti-VEGF antibody bevacizumab as
tools to study IMO’s role on EGFR and angiogenesis and to explore
its therapeutic potential in GEO, LS174T, and GEO-CR cancer xeno-
grafts. We found that IMO enhances the antibody-dependent
cell-mediated cytotoxicity (ADCC) activity of cetuximab, that bev-
acizumab has no ADCC, and IMO is unable to enhance it. Never-
theless, the IMO-plus-bevacizumab combination synergistically in-
hibits the growth of GEO and LS174T as well as of GEO-CR tumors,
preceded by inhibition of signaling protein expression, microvessel
formation, and human, but not murine, VEGF secretion. Moreover,
IMO inhibited the growth, adhesion, migration, and capillary
formation of VEGF-stimulated endothelial cells. The antitumor
activity was irrespective of the TLR9 expression on tumor cells.
These studies demonstrate that synthetic agonists of TLR9 inter-
fere with growth and angiogenesis also by EGFR- and ADCC-
independent mechanisms affecting endothelial cell functions and
provide a strong rationale to combine IMO with bevacizumab and
EGFR inhibitory drugs in colon cancer patients.
angiogenesis  cancer therapy  growth factor receptors
Activation of Toll-like receptor 9 (TLR9) by DNA containingunmethylated CpG motifs, its natural ligand, produces
potent Th1-type innate and adaptive immune responses (1).
TLR9-stimulated B cells and plasmacytoid dendritic cells secrete
a number of Th-1-promoting cytokines and chemokines, includ-
ing IL-12, IL-6, IFN-, Type 1 IFNs, MIP-1, and IP-10 (2–4).
Agonists of TLR9 have shown antitumor activity, alone and in
combination with chemotherapy and radiotherapy, and ability to
enhance the antibody-dependent cell-mediated cytotoxicity
(ADCC) of mAbs in a number of preclinical and early clinical
trials (3, 5).
Based on extensive structure–activity relationship studies,
synthetic agonists of TLR9 containing novel DNA structures and
synthetic dinucleotide motifs, referred to as immune modulatory
oligonucleotides (IMOs), have been synthesized, demonstrating
distinct cytokine profiles in vitro and in vivo, compared with
conventional TLR9 agonists (4, 6, 7) and higher metabolic
stability due to the novel DNA structure present in them (8–10).
Previous studies have demonstrated potent antitumor activity of
IMOs as monotherapies and in combination with chemothera-
peutic agents and mAbs (11, 12). Currently, a synthetic agonist
of TLR9, IMO-2055, is under clinical evaluation, in combination
with chemotherapy and other agents in cancer patients.
Intriguingly, although the TLR9 immunologic mechanisms are
fairly well understood, and the clinical development of TLR9
agonists is very encouraging, the mechanisms by which they
affect signaling proteins involved in tumor growth and angio-
genesis, thus leading to tumor growth inhibition, have yet to be
elucidated.
The epidermal growth factor receptor (EGFR) plays a pivotal
role in the control of cell growth, apoptosis, and angiogenesis (13),
and EGFR blockade by mAbs or small-molecule tyrosine kinase
inhibitors has now entered clinical practice in patients affected by
different types of cancer, including colorectal (14, 15).
We have recently demonstrated that an IMO inhibits the
expression and function of activated EGFR and of other critical
downstream proteins (12). IMO exhibited a synergistic antitu-
mor effect with the anti-EGFR mAb cetuximab or the tyrosine
kinase inhibitor gefitinib in GEO human colon cancer xeno-
grafts, whereas it was ineffective against the cetuximab-resistant
tumors GEO cetuximab-resistant (GEO-CR) (12). These find-
ings have opened the path to clinical studies combining IMO
with EGFR inhibitors in cancer patients.
We and others have previously shown that colon tumors,
including GEO-CR, that acquire resistance to the anti-EGFR
drugs cetuximab or gefitinib overexpress and secrete VEGF,
which acts as an escape pathway, overcoming the EGFR block-
ade (16, 17). Moreover, it has been shown that VEGF overex-
pression markedly impairs the activity of dendritic cells and the
antitumor immune response (18, 19). These studies and our
demonstration of a cooperative effect of cetuximab with a
selective inhibitor of VEGF (20) have provided the basis for the
ongoing clinical studies combining inhibitors of EGFR and of
VEGF/VEGF receptors (21, 22). Currently, the anti-VEGF
mAb bevacizumab is successfully used in combination with
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chemotherapy for the treatment of colorectal cancer (23) and
has shown efficacy also in nonsmall-cell lung and breast cancer
(24). Interestingly, the VEGF blockade by bevacizumab recovers
the activity of dendritic cells, improving their antitumor function
(18, 19). In the former study, we observed a potent inhibitory
effect of IMO and cetuximab on VEGF and angiogenesis in
wild-type but not in GEO-CR colon tumors, suggesting that the
anti-VEGF effect is only EGFR-dependent. To address this
issue, provide insight into the mechanism of action of IMO on
signaling and angiogenesis, and explore the therapeutic potential
of the association of IMO with a specific VEGF inhibitor, we
have evaluated the effects of IMO in combination with bevaci-
zumab on the growth, signaling, and angiogenesis of different
wild-type and cetuximab-resistant colon cancer models.
Results
Bevacizumab Has No ADCC Activity, and IMO Is Unable to Affect It. To
investigate the capability of bevacizumab to activate an ADCC
reaction in cancer cells and the influence of IMO in a combi-
nation treatment, we performed a cytotoxic assay using the
conventional target MDA-468, a human breast cancer line that
expresses both EGFR and VEGF receptors. As expected, in the
absence of antibodies, freshly isolated nonadherent human
peripheral blood lymphocytes (PBLs) were able to kill the
standard NK-target K562 cells but did not induce any detectable
lysis of MDA468 cells (Fig. 1). The same result was obtained
when PBLs were incubated with IMO. Conversely, the anti-
EGFR mAb cetuximab, which possesses a formerly described
ADCC mechanism (25), caused a 40% induction of MDA-468
lysis. Preincubation of PBLs with IMO potentiated up to 60% of
the MDA-468 killing induced by cetuximab (Fig. 1). On the
contrary, preincubation of PBLs with IMO did not affect the
inability of bevacizumab to produce the lysis of MDA-468 cells.
Therefore, bevacizumab, as well as the combination of IMO and
bevacizumab, has no ADCC.
Combination of Bevacizumab with IMO Synergistically Inhibits GEO
and LS174T Colon Cancer Xenografts. BALB/c nude mice xe-
nografted with GEO and LS174T tumors were treated with IMO
or bevacizumab, alone and in combination (Fig. 2). On day 56,
8 weeks after tumor injection, all untreated mice xenografted
with GEO cells reached the maximum allowed tumor size of 2
cm3, whereas mice treated with IMO alone exhibited 50%
growth inhibition, having a size of 1 cm3. Treatment with
bevacizumab produced a 35% inhibition, because tumors mea-
sured 1.3 cm3 at the same time point. The combination of IMO
plus bevacizumab caused a potent cooperative antitumor activ-
ity, with 95% growth inhibition (tumor size of only 0.12 cm3)
(Fig. 2A).
Similar effects were observed in LS174T xenografts. The
maximum allowed size of 2 cm3 was reached on day 35 in the
untreated mice. On day 56, at the end of the experiment, mice
treated with IMO or bevacizumab alone measured 1.6 and 1
cm3, respectively, whereas those treated with the two agents in
combination showed a potent cooperative tumor growth inhi-
bition of 95% compared with untreated animals, resulting in a
Fig. 1. ADCC assay. The effector cells (human PBLs) were incubated in the
presence or absence of IMO and then mixed with the target cells (K562 and
MDA468), which were incubated in the presence or absence of the antibodies
cetuximab and bevacizumab. Doses and time of administration are indicated
in Materials and Methods.
Fig. 2. Cooperative effect of IMO and bevacizumab on tumor growth of mice
bearing human colon cancer xenografts. Seven days after tumor cell injection,
mice were randomized (10 per group) to receive the following treatments: i.p.
IMO, 1 mg/kg three times per week for 4 weeks; i.p. bevacizumab, 5 mg/kg,
twice per week for 3 weeks, or the combination of these agents on days 7–11,
14–18, and 21–25, continuing only IMO on days 28–32. Two mice were killed
at day 25 for biochemical and histochemical analyses. Student’s t test was used
to compare tumor sizes among different treatment groups at day 56 after GEO
(A) and LS174T (B) cell injection. The results were statistically significant for
IMO plus bevacizumab vs. control (two-sided P  0.0001), vs. IMO alone
(two-sided P  0.0001), and vs. bevacizumab alone (two-sided P  0.0001) in
both experiments. Error bars indicate SD.
Damiano et al. PNAS  July 24, 2007  vol. 104  no. 30  12469
M
ED
IC
A
L
SC
IE
N
CE
S
tumor size of 0.16 cm3 (Fig. 2B). No treatment-related side
effects were observed in either tumor model studied. Compar-
ison of tumor sizes among different treatment groups, evaluated
by Student’s t test, was statistically significant both in GEO and
LS174T tumors (Fig. 2).
Combination of Bevacizumab with IMO Inhibits the Expression of
Signaling Proteins and Angiogenesis in GEO and LS174T Xenografts
and Reduces the Levels of Human VEGF (hVEGF), but Not of Murine
VEGF (mVEGF), in Mice Serum.We analyzed the effect of treatment
on the expression of a variety of proteins playing a critical role
in cancer cell proliferation and angiogenesis. Western blot
analysis was performed on cell lysates from tumors removed at
the end of the third week of treatment, on day 25. As shown in
Fig. 3 A and B, IMO did not affect the total amount of MAPK
and Akt but inhibited their activated forms pMAPK and pAkt
and VEGF expression. Bevacizumab inhibited the same signal-
ing proteins, although to a lesser degree compared with IMO.
When the two agents were used in combination, a more potent
inhibition was observed on protein expression. To confirm the
effect of a combination of bevacizumab with IMO on hVEGF
levels, we performed ELISA on the serum obtained from
LS174T-bearing mice (Fig. 3 C and D). Because bevacizumab
recognizes only hVEGF, as expected, it caused a reduction in the
levels of circulating hVEGF in the serum. The treatment with
IMO alone reduced the secreted hVEGF levels, and the com-
bination with bevacizumab caused a more potent inhibition of
circulating hVEGF levels compared with treatment with single
agents (Fig. 3C). On the contrary, neither single agent nor the
combination affected mVEGF compared with untreated mice
(Fig. 3D).
Immunohistochemical analysis of LS174T tumor specimens
performed during the third week of treatment revealed a mod-
erate induction of necrosis caused by IMO treatment and, at a
higher degree, by bevacizumab. The combination of the two
agents caused a massive hemorrhagic necrosis (in 90% of the
tumor). Furthermore, analysis of microvessels demonstrated
25% inhibition of CD34-stained host vessels in the animals
treated with IMO and 40% inhibition after bevacizumab
treatment compared with untreated mice. The specimen from
mice treated with the two agents in combination showed an
inhibition of vessels formation up to 75%.
Combination of Bevacizumab with IMO Causes Potent Antitumor
Activity in Cetuximab-Resistant GEO-CR Xenografts. We evaluated
whether a cooperative effect could be obtained in cetuximab-
resistant GEO-CR tumors, in the absence of an ADCC effect.
We have shown that IMO alone is ineffective, whereas bevaci-
zumab markedly inhibited GEO-CR growth (Fig. 4A). When
IMO was used in combination with bevacizumab, a cooperative
inhibitory effect was observed, because at the end of the
experiment, tumors were still 0.15 cm3 (Fig. 4A). With the
exception of the mice treated with IMO alone, Student’s t test
demonstrated that the growth inhibition caused by each treat-
ment, in comparison with untreated mice as well as the tumor
size among different treatment groups, was statistically different
(Fig. 4).
Western Blot Analysis of GEO-CR Tumors. Western blot analysis of
protein extracts from GEO-CR tumors did not reveal any
substantial changes in the expression of pAkt, pMAPK, and
VEGF in tumor specimens treated with IMO alone, whereas a
marked inhibition was seen in those treated with bevacizumab or
with the combination IMO plus bevacizumab (Fig. 4B).
IMO Inhibits Survival, Adhesion to Matrix, Migration, and Capillary
Formation Capability in Human Endothelial Cells. To evaluate
whether antiangiogenic activity of IMO could be linked also to
a direct effect on human endothelial cells, we performed a cell
survival assay on human umbilical vein endothelial cells
(HUVEC). At doses of 1 and 5 M, IMO caused a moderated
inhibition of HUVEC survival, which was increased by the
addition of lipofectamine, an agent that facilitates cellular
uptake of IMO (Fig. 5A). We then analyzed the effects of IMO
on HUVEC adhesion and migration by using a cell adhesion
assay to matrigel and a wound-healing assay. At 1 M concen-
tration, IMO showed a potent inhibitory activity on adhesion and
migration of endothelial cells (Fig. 5 B and C). Finally, we
examined the effects of IMO onVEGF-stimulated capillary tube
and network formation and observed that this process is strongly
inhibited by IMO (Fig. 5D).
Fig. 3. Western blot analysis of GEO (A) and LS174T (B) tumors and ELISA on
mice serum (C and D). (A and B) Western blot analysis was performed on total
lysates from tumor specimens of two mice killed on day 25 and treated as in
Fig. 1. (C andD) ELISA for hVEGF and mVEGF were performed on the serum of
two mice killed on day 25 and treated as in Fig. 2. Doses and time of
administration are indicated in Materials and Methods. Lane 1, untreated
control; lane 2, IMO; lane 3, bevacizumab; and lane 4, IMO plus bevacizumab.
Fig. 4. Effect of the combination of IMO with bevacizumab in mice bearing
cetuximab-resistant GEO-CR tumor xenografts. (A) Seven days after GEO-CR
tumor injection, mice were randomized (10 per group) to receive i.p. IMO, 1
mg/kg three times per week for 4 weeks; i.p. bevacizumab, 5 mg/kg, twice per
week for 3 weeks, or the combination of these agents, on days 7–11, 14–18,
and 21–25, continuing only IMO on days 28–32. Inhibition of growth was
significantly different in the IMO plus bevacizumab-treated group vs. the
control group, the IMO alone group, and the bevacizumab alone group
(two-sided P  0.0001 for each comparison). (B) Western blot analysis was
performed on total lysates from tumor specimens of two mice killed on day 25
and treated as in Fig. 2. Lane 1, untreated control; lane 2, IMO; lane 3,
bevacizumab; and lane 4, IMO plus bevacizumab. Doses and time of admin-
istration are indicated in Materials and Methods. Error bars indicate SD.
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TLR9 Is Expressed in LS174T, GEO, and GEO-CR Cells but Does Not
Affect Their Growth in Vitro. We analyzed TLR9 expression in
LS174T, GEO, and GEO-CR cell lines. In an earlier study, we
were unable to detect TLR9 on GEO cells by using a direct
Western blot assay (12). We have now used a more recent
antibody (see Materials and Methods) and assayed each sample
by immunoprecipitation followed by Western blot analysis,
revealing a different degree of TLR9 protein expression in all
cell lines. Further, the RT-PCR assay confirmed TLR9 mRNA
expression in all of the cell lines examined (Fig. 6). We then
investigated whether IMO could directly affect cell survival.
Treatment of these cells with IMO at doses ranging from 0.1 to
1 M, with or without lipofectamine, did not produce any effect
on cell proliferation (data not shown).
Discussion
Synthetic agonists of TLR9 are a class of compounds with
antitumor activity that have entered the clinical evaluation in
cancer patients in combination with chemotherapy (3). Although
it is well documented that TLR9 agonists induce a potent innate
and adaptive immune response and enhance theADCCofmAbs,
the mechanisms by which they affect growth signaling and
angiogenesis are yet poorly understood.
We have recently hypothesized and demonstrated that a
synthetic agonist of TLR9 (IMO) impairs EGFR and its down-
stream signaling proteins, including VEGF (12). The combina-
tion of IMO with anti-EGFR mAb cetuximab or tyrosine kinase
inhibitor gefitinib, synergistically inhibits GEO tumor growth,
the expression of several critical proteins and angiogenesis.
Conversely, IMO is inactive against cetuximab-resistant
GEO-CR tumors, further suggesting its dependence on EGFR
signaling (12).
The EGFR pathway has a strong correlation with VEGF. In
fact, EGFR can transactivate VEGF production (26, 27) and
VEGF overexpression is a major escape pathway used by colon
cancer, including GEO-CR tumors, to acquire resistance to
EGFR antagonists (16, 21, 28, 29). This notion was recently
confirmed in colon cancer patients failing treatment with cetux-
imab (30). On these bases, recently bevacizumab has been
successfully used also in combination with EGFR inhibitors (22).
Interestingly, VEGF impairs dendritic cell function, a major
target of TLR9 agonists, and bevacizumab can overcome such
interference (18, 19). We have previously shown that IMO fails
to inhibit the growth as well as VEGF expression in GEO-CR
tumors, suggesting that the interference of IMO with VEGF
observed in wild-type tumors is actually an EGFR-dependent
activity (12).
Based on the above studies, in the present work, we have
analyzed the role played by IMO on these signaling pathways and
its therapeutic implications. In particular, we have studied
whether: (i) the potent inhibitory effect obtained with IMO and
cetuximab on VEGF and angiogenesis depends on or is inde-
pendent of interference in the EGFR pathway; (ii) the depen-
dence of IMO on an integral EGFR pathway may affect its
combination with an anti-VEGF agent, such as bevacizumab;
and (iii) the ADCC mechanism and the expression of TLR9 are
necessary to obtain a cooperative effect with mAbs.
To this aim, we combined IMO with bevacizumab, taking
advantage of the fact that bevacizumab targets only the tumor-
produced hVEGF and does not interfere with the mVEGF. Be-
cause bevacizumab binds the ligand and not the membrane recep-
tor, we verified whether it has any ADCC activity, and whether
IMO affects it. We have shown that the basal ADCC activity of
cetuximab is enhanced by IMO in an in vitro assay, thus contributing
to cetuximab activity with an EGFR-independent mechanism.
Fig. 5. IMO effects on HUVEC survival (A), adhesion to matrix (B), migration
(C), and tube formation (D). (A) HUVEC were treated with IMO, 1 and 5 M,
in the presence or absence of Lipofectamine (2 g/ml). The results are statis-
tically significant for each dose of IMO vs. control (two-sided P  0.0001). (B)
HUVEC plated in the presence or absence of 1 M IMO in serum-free medium
(negative control) or Matrigel. The results are statistically significant for
Matrigel vs. the negative control and for IMO vs. Matrigel (two-sided P 
0.0001). (C) HUVEC monolayers were wounded in the absence or presence of
10 ng/ml doxorubicin or 1 M IMO (0 h). The results are statistically significant
for IMO vs. control and vs. doxorubicin (two-sidedP0.0001). (D) HUVEC were
incubated with diluted Matrigel in the presence or absence of 1 M IMO.
Matrigel mixed with 100 ng/ml VEGF was used as positive control. Photo-
graphs were taken at 0 and 24 h.
Fig. 6. Evaluation of TLR9 expression in human colon cancer cell lines. (A)
TLR9 mRNA expression was evaluated in cultured LS174T, GEO, and GEO-CR
colon cancer cell lines. (B) TLR9 expression was confirmed at the protein level
by using immunoprecipitation and blotting with the same monoclonal anti-
TLR9 antibody. PBMCs were included as positive control as well as RT-PCR
targeting human GAPDH. Lane 1, PBMCs; lane 2, LS174T; lane 3, GEO; and lane
4, GEO-CR.
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Conversely, bevacizumab has noADCCactivity, and IMO is unable
to affect it. We have then demonstrated that the combination of
bevacizumab with IMO causes a synergistic inhibition of tumor
growth in human colon cancer xenografts GEO and LS174T and in
the cetuximab-resistant GEO-CR, resulting in 90% of mice being
tumor-free at pathologic analysis at the end of the experiment, 4
weeks after treatment withdrawal. Therefore, this combination
treatment is also very effective in anti-EGFR-resistant tumors in an
ADCC-independent fashion, suggesting that other mechanisms,
not strictly EGFR- and ADCC-dependent, take place. In support
of this notion, the two agents in combination cooperatively inhibit
the expression of proteins used by tumors as escape pathways to
acquire resistance to targeted therapies, such as pMAPK, pAkt, and
VEGF (29) and inhibit neoangiogenesis in all three tumor types.
Analysis of the secreted VEGF in the serum of killed mice
confirmed that bevacizumab, as expected, reduces the hVEGF
levels, and also that the combination of IMO and bevacizumab
cooperates in reducing the levels of hVEGF but not mVEGF.
These results suggest that themurine-dependent immune-mediated
effects of IMO enhance the activity of bevacizumab only on the
human tumor cells. Interestingly, IMO and bevacizumab in com-
bination caused a massive hemorrhagic necrosis, evaluated by
pathological and immunohistochemical analysis, as early as the
third week of treatment. An important mechanism of antiangio-
genic therapy is the blockade of theVEGF-dependent proliferation
of endothelial cells in the tumor. In an attempt to provide a clue to
explain the non-EGFR-dependent cooperative antiangiogenic ef-
fects obtained with IMO and bevacizumab, we measured their
activity on several functions of endothelial cells. We demonstrated
that IMO inhibits proliferation, adhesion, and migration of
HUVEC endothelial cells and, importantly, the VEGF-stimulated
capillary tube and network formation. Therefore, it is likely that the
well documented inhibitory effect of bevacizumab on vessel for-
mation, due toVEGF inhibition, combinedwith the interference of
IMO on critical functions of tumor endothelial cells, may finally be
responsible for the cooperative effect observed. In addition, be-
cause it has been reported that colon cancer cell lines, including
GEO, express VEGF receptors (31), the combined effect of IMO
and bevacizumab may have a direct impact also on tumor cells.
Together, these data may also help explain, at least in part, the
hemorrhagic necrosis observed in the LS174T tumors.
Finally, we attempted to understand the relevance of TLR9
expression for the antitumor effects observed. Measurement of
TLR9 by different techniques demonstrated the presence of
mRNA and protein expression, to a different degree, in GEO,
LS174T, and GEO-CR cells. Nevertheless, treatment of these
cells in vitro with IMO, at different doses, with or without
lipofectamine to improve cellular penetration, did not produce
any effect on tumor growth or on EGFR expression. In addition,
the in vivo effect of IMO with or without bevacizumab was not
proportional to the degree of TLR9 expression. Therefore, the
expression of TLR9 on these colon tumor cells is not directly
responsible for the antitumor effects observed but is more likely
related to the systemic immune responses produced by IMO.
Taken together, these studies provide insights into the mech-
anisms of action of synthetic agonists of TLR9. In fact, they
demonstrate that, although dependent on the immune activa-
tion, IMO has a much broader range of mechanisms, involving
not only the EGFR-dependent pathway but also the neoangio-
genesis. These results provide a strong rationale to translate the
combination with bevacizumab in the clinical practice, as a
potentially powerful and rationally based therapeutic strategy.
The possibility of combining IMO with inhibitors of EGFR and
of VEGF creates the opportunity to take advantage of multiple
chance for cooperativity, involving EGFR- and ADCC-
dependent and -independent mechanisms and neoangiogenesis.
Materials and Methods
Compounds. IMO, 5-TCTGACRTTCT-X-TCTTRCAGTCT-5
(X and R are the glycerol linker and 2-deoxy-7-deazaguanosine,
respectively) was synthesized with phosphorothioate backbone,
purified, and analyzed as described (6–8, 32). The mAb anti-
VEGF bevacizumab was kindly provided by Genentech (South
San Francisco, CA).
Cell Cultures. GEO, LS174T, GEO-CR (16) colon cancer cells,
and HUVEC were maintained, respectively, in McCoy’s or
RPMI medium 1640 supplemented with 10% heat-inactivated
FBS/20 mM Hepes, pH 7.4/penicillin (100 units/ml)/streptomy-
cin (100 g/ml)/4 mM glutamine (ICN, Irvine, CA) in a humid-
ified atmosphere of 95% air and 5% CO2 at 37°C.
ADCC Assay. A nonadherent fraction of human peripheral blood
mononuclear cells (PBMCs) was used as effector cells. Briefly,
humanPBMCswere isolated by density gradient centrifugation and
resuspended in RPMI medium 1640. Before the assay, the PBMCs
were cultured for 1 h on plastic dishes to remove adherent cells
(monocytes), and then the PBLs were incubated for 24 h in the
presence or absence of IMO (5 M). The target cells (chronic
erythroid leukemia K562 and breast cancerMDA468) were loaded
with the fluorescence-enhancing ligand (DELFIA BATDA re-
agent; PerkinElmer, Wellesley, MA) and, after washing, were
incubated in the presence or absence of the antibodies bevacizumab
or cetuximab (10g/ml). Target cells weremixed with effector cells
at varying cell concentrations for 2 h at 37°C and centrifuged.
Supernatants were added to Europium solution and the signal was
measured, as described (33).
Xenografts in Nude Mice. Five-week-old BALB/cAnNCrlBR athy-
mic (nu/nu) mice (Charles River Laboratories, Milan, Italy)
were maintained in accordance with the institutional guidelines
of the University of Naples Animal Care Committee in accor-
dance with the Declaration of Helsinki. Wild-type GEO,
LS174T, or GEO-CR human colon cancer cells (107 cells per
mouse) were resuspended in 200 l of Matrigel (Collaborative
Biomedical Products, Bedford, MA) and injected s.c. in mice.
After 7 days, tumors were detected, and groups of 10 mice were
randomized to receive the following treatments: i.p. IMO, 1
mg/kg, three times per week for 4 weeks; i.p. bevacizumab, 5
mg/kg, twice per week for 3 weeks; or the combination of these
agents, on days 7–11, 14–18, and 21–25, continuing only IMO on
days 28–32. Tumor volume was measured by using the formula
/6  larger diameter  (smaller diameter)2, as reported (34).
Two mice were killed on day 25 for biochemical analysis.
Immunoprecipitation and Western Blot Analysis. Total cell lysates
were obtained from homogenized tumor specimens removed on
day 25. The protein extracts were resolved by 4–15% SDS/PAGE
and probed with anti-human polyclonal Akt, monoclonal pAkt
(Cell Signaling Technologies, Beverly, MA), monoclonal actin
(Sigma-Aldrich, Milan, Italy), monoclonal VEGF, monoclonal
pMAPK, and monoclonal MAPK (Santa Cruz Biotechnology,
Santa Cruz, CA). Immunoreactive proteins were visualized by
enhanced chemiluminescence (Pierce, Rockford, IL), as de-
scribed (16). TLR9 protein levels were evaluated on total cell
lysates by immunoprecipitation by using a monoclonal anti-
TLR9 antibody (Calbiochem/EMD Biosciences, La Jolla, CA)
and blotting with the same antibody, following the procedures
described above.
Immunohistochemical Analysis. Immunocytochemistry was per-
formed on formalin-fixed paraffin-embedded tissue sections (5
m) of LS174T xenografts. Sections were processed, reacted
with avidin-conjugated horseradish peroxidase H complex, and
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stained as described (34). New blood vessels were detected by
using a mAb against the CD34 antigen (Dako, Milan, Italy) at a
dilution of 1:50 and stained with a standard immunoperoxidase
method (Vectastain ABC kit; Vector Laboratories, Burlingame,
CA). Each slide was scanned at low power (10–100 magnifi-
cation), and the area with the higher number of new vessels was
identified (hot spot). This region was then scanned at 250
magnification (0.37 mm2). The number of microvessels per field
was scored by averaging five field counts of two individual
tumors for each group.
ELISA. Anti-hVEGF or anti-mVEGF polyclonal antibody (R&D
Systems, Minneapolis, MN), diluted at 1 g/ml in PBS, pH 7.5,
was used to coat a 96-well plate, 100 l/well, overnight at 4°C.
Washings, dilutions of standards (recombinant hVEGF or
mVEGF), and samples (serum of killed mice), biotinylation, and
mix with preformed avidin and biotinylated HRP macromolec-
ular complex (Vectastain kit) were described (35). The absor-
bance was measured at 490 nm on a microplate reader (Bio-Rad,
Hercules, CA). VEGF concentrations were determined by in-
terpolation of the standard curve by using linear regression
analysis.
RT-PCR. Total RNA was extracted by using the TRIzol reagent
from Invitrogen Life Technologies (Grand Island, NY) and was
quantified and used to create cDNA. Amplification of TLR9 was
accomplished by using primers as published (36), and a portion
of the PCR product was visualized by using ethidium bromide on
an agarose gel. Human GAPDH was coamplified with TLR9 to
verify the quality and expression level of the mRNA.
Cell Survival Assay.Cells were grown in 24-well plates and exposed
to IMO with or without Lipofectamine 2000 (2 g/ml) from
Invitrogen Life Technologies. The percentage of cell survival
was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay according to the
manufacturer’s instructions.
Adhesion Assay. Ninety-six-microwell bacterial culture plates
were precoated with 50 l/well of serum-free medium (SFM)
containing 0.1% BSA (negative control) or Matrigel (1 mg/ml in
water). After 1 h, all coating solutions were removed, and
HUVEC (20,000 cells per well) were plated in SFM, in the
presence or absence of 1 M IMO. After incubation, cells were
analyzed as described (37).
Wound-Healing Assay. Monolayers of HUVEC were grown on
gridded plastic dishes and scratched as reported (38) with or
without 10 ng/ml doxorubicin or 1 M IMO (0 h), which have the
same antiproliferative effect. Because doxorubicin did not in-
terfere with cell migration, it was used as a negative control. The
migration distances between the edges of the cells in the wound
were photographed (10 magnification) at 0 and 24 h, quanti-
fied, and compared by using Adobe Photoshop, Ver. 8.0.1 (38).
Vascular Endothelial Cell Capillary Tube and Network Formation. Five
hundred microliters of diluted Matrigel was added into a 30-mm
culture dish and incubated at 37°C for 30 min. After the Matrigel
was solidified, HUVEC (4 105) in 1 ml of RPMI medium 1640
were added in each dish, in the presence or absence of 1 M
IMO, incubated at 37°C, and photographed (10) at 0 and 24 h.
As a positive control, Matrigel was mixed with 100 ng/ml VEGF
(R&D Systems).
Statistical Analysis. Student’s t test was used to evaluate the
statistical significance of the results. All reported P values were
two-sided. All analyses were performed with the BMDP New
System statistical package for Microsoft Windows (Version 1.0;
BMDP Statistical Software, Los Angeles, CA).
This paper is dedicated to the memory of Dr. Y.-S. Cho-Chung. We
acknowledge the excellent technical assistance of Gaetano Borriello. This
study was supported by grants from the Associazione Italiana per la Ricerca
sul Cancro, the Ministry of Health, and the Regione Campania.
1. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M,
Hoshino K, Wagner H, et al. (2000) Nature 408:740–745.
2. Tokunaga T, Yano O, Kuramoto E, Kimura Y, Yamamoto T, Kataoka T,
Yamamoto S (1992) Microbiol Immunol 36:55–66.
3. Krieg AM (2006) Nat Rev Drug Discov 5:471–484.
4. Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX,
Sullivan T, et al. (2005) Proc Natl Acad Sci USA 102:6925–6930.
5. van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, van Vugt MJ, van
de Winkel JG, Weiner GJ (2003) Cancer Res 63:5595–5600.
6. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang
JY, Knetter CF, et al. (2003) Proc Natl Acad Sci USA 100:14303–14308.
7. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang
P, Zhang R, et al. (2003) Nucleic Acids Res 31:2393–2400.
8. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J, Agrawal S (2002)
Nucleic Acids Res 30:4460–4469.
9. Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S (2002) Bioconjug
Chem 13:966–974.
10. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S (2005) Vaccine 23:2614–2622.
11. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S (2004) Int J Oncol
74:901–908.
12. Damiano V, Caputo R, Bianco R, D’Armiento FP, Leonardi A, De Placido S,
Bianco AR, Agrawal S, Ciardiello F, et al. (2006) Clin Cancer Res 12:577–583.
13. Mendelsohn J, Baselga J (2006) Semin Oncol 33:369–385.
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets
D, Mueser M, Harstrick A, et al. (2004) N Engl J Med 351:337–345.
15. Saltz LB, Meropol NJ, Lochrer PJ, Sr, Needle MN, Kopit J, Mayer RJ (2004)
J Clin Oncol 22:1201–1208.
16. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D,
De Vita F, De Placido S, et al. (2004) Clin Cancer Res 10:784–793.
17. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak
J, Kerbel RS (2001) Cancer Res 61:5090–5101.
18. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP
(1998) Blood 92:4150–4166.
19. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP (1999) Clin Cancer
Res 5:2963–2970.
20. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De
Placido S, BiancoAR,Mendelsohn J, et al. (2000)Clin Cancer Res 6:3739–3747.
21. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E,
Morelli MP, Cascone T, Tortora G (2006) Ann Oncol 17:109–114.
22. Sandler A, Herbst R (2006) Clin Cancer Res 12:4421–4425.
23. Hurwitz H, Kabbinavar F (2005) Oncology 69:17–24.
24. Gasparini G, Longo R, Toi M, Ferrara N (2005) Nat Clin Pract Oncol 2:562–577.
25. Fan Z, Masui H, Altas I, Mendelsohn J (1993) Cancer Res 53:4322–4328.
26. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS
(1997) Am J Pathol 151:1523–1530.
27. Perrotte P, Matsumoto T, Inoue K, Kunivasu H, Eve BY, Hicklin DJ, Radinsky
R, Dinney CP (1999) Clin Cancer Res 5:257–265.
28. Viloria-Petit AM, Kerbel RS (2004) Int J Radiat Oncol Biol Phys 1:914–926.
29. Bianco R, Troiani T, Tortora G, Ciardiello F (2005) Endoc Relat Cancer 12:159–171.
30. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE,
Sherrod AE, Iqbal S, et al. (2005) J Clin Oncol 23:3536–3544.
31. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer T, Somcio RJ, Wu Y,
Hooper A, et al. (2005) Oncogene 24:2647–2653.
32. YuD, Zhu FG, Bhagat L,WangH, Kandimalla ER, ZhangR, Agrawal S (2002)
Biochem Biophys Res Commun 297:83–90.
33. Blomberg K, Hautala R, Lovgren J, Mukkala VM, Lindgvist C, Akerman K
(1996) J Immunol Methods 193:199–206.
34. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M,
De Placido S, Mendelsohn J, Bianco AR, et al. (1996) J Natl Cancer Inst
88:1770–1776.
35. Errico M, Riccioni T, Iyer S, Pisano C, Acharya KR, Persico MG, De Falco
S (2004) J Biol Chem 279:43929–43939.
36. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E,
Dalhoff K, Zabel P, Goldmann T (2005) Respir Res 6:1.
37. Benelli R, Peissel B, Manenti G, Gariboldi M, Vanzetto C, Albini A, Dragani
TA (2003) Oncogene 22:7711–7715.
38. Bennett RD, Mauer AS, Strehler EE (2007) J Biol Chem 282:3205–3212.
Damiano et al. PNAS  July 24, 2007  vol. 104  no. 30  12473
M
ED
IC
A
L
SC
IE
N
CE
S
